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Abstract
Inherited retinal degenerative diseases are one of the leading causes of childhood blindness. While over
200 causative genes have been identified, many cases still have an unknown underlying genetic cause.
With the advent of next generation sequencing (NGS), it should be possible to identify the genetic cause
in almost every case, provided enough relatives are willing to participate. However, the massive amount of
data generated by NGS can make identifying the pathogenic variant challenging. It is necessary to filter
the data in order to create a manageable candidate list, but overly strict filtering or erroneous
assumptions can result in filtering out the pathogenic variant. Identifying the genetic cause of retinal
degeneration in each patient will allow us to better identify candidate genes for gene therapy and bring us
a step closer to precision medicine. Here we developed an efficient screening system to find candidate
mutations with minimal assumptions to avoid screening out pathogenic variants and better identify good
candidates for novel gene discovery. Out of an initial cohort of 69 patients we identify the pathogenic
variant(s) in 44 of them and identified 11 subjects as good candidates for novel gene discovery.
We also need a broad treatment for retinal degeneration to help those who have mutations in genes that
are poor candidates for gene therapy or who have an unknown genetic cause. We tested the efficacy of
using the GRM6 minimal promoter as a bipolar cell specific promoter to express channelrhodopsin in
bipolar cells after photoreceptor degeneration to make the bipolar cells directly respond to light.
Surprisingly, we found that unlike in the wildtype mouse retina, the GRM6 promoter is not bipolar cell
specific in multiple mouse models of retinal degeneration. This suggests that the genetic profiles of the
cells in the inner retina change during retinal degeneration. Understanding these fundamental changes in
cell specific gene expression during retinal degenerative processes will be critical in order to develop
effective therapeutic strategies for late stage retinal degeneration.
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ABSTRACT
GENES AND RETINAL DEGENERATION: CHALLENGES IN OPTOGENETICS
THERAPY AND IDENTIFYING PATHOGENIC VARIANTS
Laura M. Bryant
Jean Bennett M.D., Ph.D.

Inherited retinal degenerative diseases are one of the leading causes of childhood
blindness. While over 200 causative genes have been identified, many cases still have an
unknown underlying genetic cause. With the advent of next generation sequencing
(NGS), it should be possible to identify the genetic cause in almost every case, provided
enough relatives are willing to participate. However, the massive amount of data
generated by NGS can make identifying the pathogenic variant challenging. It is
necessary to filter the data in order to create a manageable candidate list, but overly strict
filtering or erroneous assumptions can result in filtering out the pathogenic variant.
Identifying the genetic cause of retinal degeneration in each patient will allow us to better
identify candidate genes for gene therapy and bring us a step closer to precision
medicine. Here we developed an efficient screening system to find candidate mutations
with minimal assumptions to avoid screening out pathogenic variants and better identify
good candidates for novel gene discovery. Out of an initial cohort of 69 patients we
identify the pathogenic variant(s) in 44 of them and identified 11 subjects as good
candidates for novel gene discovery.
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We also need a broad treatment for retinal degeneration to help those who have mutations
in genes that are poor candidates for gene therapy or who have an unknown genetic
cause. We tested the efficacy of using the GRM6 minimal promoter as a bipolar cell
specific promoter to express channelrhodopsin in bipolar cells after photoreceptor
degeneration to make the bipolar cells directly respond to light. Surprisingly, we found
that unlike in the wildtype mouse retina, the GRM6 promoter is not bipolar cell specific
in multiple mouse models of retinal degeneration. This suggests that the genetic profiles
of the cells in the inner retina change during retinal degeneration. Understanding these
fundamental changes in cell specific gene expression during retinal degenerative
processes will be critical in order to develop effective therapeutic strategies for late stage
retinal degeneration.
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Chapter 1: Introduction
Phenotype and genotype variability in inherited retinal degeneration
Hereditary retinal degeneration causes blindness independent of environmental factors,
with disease onset often occurring during childhood. This includes non-syndromic forms
like Stargardt disease, Leber’s congenital amaurosis (LCA), retinitis pigmentosa (RP),
achromatopsia and cone-rod dystrophy (CORD) as well as syndromic forms like BardetBiedl syndrome (BBS), Usher’s syndrome and Batten disease. Typically, hereditary
retinal degeneration is monogenic and has an earlier onset than other causes of retinal
degeneration like glaucoma or age related macular degeneration. In some forms, such as
LCA, disease onset is very young, before the age of 51. Others, like RP and Stargardt can
have an adult onset2,3. Retinal dystrophy can be inherited in every known inheritance
pattern including autosomal dominant (sometimes with incomplete penetrance),
autosomal recessive, X-linked and sporadic. There is a huge variability in disease
presentation and progression. Stargardt disease primarily affects cones while RP
primarily affects rods4,5. More severe diseases like LCA start by affecting rods but
eventually cause secondary cone degeneration6. Other forms, such as cone dystrophy,
largely preserve rod function, even in the most advanced disease state7. Some forms of
retinal degeneration cause different patterns of degeneration or include deposits in the
subretinal space. The hallmark feature of Stargardt disease is yellow flecks in the
macula, which are lipofuscin deposits in the subretinal space3,4,8. This is not seen in other
forms of retinal degeneration. Meanwhile, bone spicules, caused by changes in the
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retinal pigment epithelial (RPE) cells after photoreceptor degeneration, are characteristic
of retinitis pigmentosa9.
Despite the huge variability seen in different forms of retinal degeneration, there is also
significant overlap in disease phenotype which can affect the ability to give an accurate
and specific diagnosis in early stages of degeneration. In particular, syndromic retinal
degeneration can appear to be non-syndromic in early stages if other symptoms have not
yet appeared or if patients fail to report the other symptoms to the ophthalmologist.
Bardet Biedl syndrome is extremely variable in severity and mild forms can be initially
diagnosed as RP10. Cone dystrophy can progress to cone rod dystrophy in some cases
while in other cases rods are spared11. Since the only difference is disease progression,
an ophthalmic exam during the early stages of the diseases cannot always provide an
exact diagnosis. When the diagnosis is being made based on the time of disease onset
and severity of degeneration, it is possible that a genetic diagnosis can modify the initial
clinical diagnosis, such as changing an initial diagnosis of RP to a late onset form of LCA
or an initial diagnosis of BBS can be changed to RP after clinical reassessment12,13.
In addition to the phenotypic variability in retinal degeneration, there is significant
genetic variability within the same phenotype. There are currently 18 genes known to
cause LCA, with a significant number of patients with no known genetic cause14-18.
Retinitis Pigmentosa can be caused by mutations in any one of over 60 genes, with
approximately 40% of cases negative for all known causes of RP19,20. Other forms have
less genetic variability. Stargardt disease, for example, is almost always caused by
mutations in ABCA4 (95% of cases)21. Many of the genes that cause retinal degeneration
2

can cause more than one form. For example, although ABCA4 causes most cases of
Stargardt disease, it can also lead to retinitis pigmentosa or cone-rod dystrophy or even
act as a disease modifying allele22-24. The same mutation in PRPH2 can cause autosomal
dominant RP or macular degeneration even within the same family25. Variants in USH2A
have been shown to cause both Usher syndrome and RP26. These are only a few of many
examples of genes that can cause more than one phenotype.
Possibilities for polygenic inheritance
To further complicate the genetics of retinal degeneration, digenic inheritance is another
possible mode of inheritance. So far only one digenic cause of retinal degeneration has
been identified (ROM1 and PRPH2), but it is likely that at least some of the remaining
cases of undetermined genetic cause will be digenic or polygenic27. Recently, a second
potential cause of digenic retinal degeneration (this time causing syndromic retinal
dystrophy) was proposed that is caused by null alleles in RP1L1 and C2orf71, but more
has to be done to conclusively prove that heterozygous mutations in these two genes are
sufficient to cause retinal degeneration in humans28.
While there is so far only one known cause of digenic inheritance, modifying alleles are
much more common and contribute to the phenotypic variability we see with some genes.
Heterozygous mutations that would not cause retinal degeneration by themselves have
been shown to contribute to disease pathogenesis when combined with a pathogenic
mutation, either alleviating or aggravating the disease phenotype. ABCA4 and ROM1 can
act as modifying alleles for PRPH2 mutations and determine rod vs cone phenotype24.
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RPGRIP1L can act as a modifying allele in ciliopathies to exacerbate (or cause) a retinal
phenotype29. While not pathogenic in isolation, these mutations are very important to
note and can help provide a more accurate clinical diagnosis and prediction of disease
progression. They can be particularly important in cases of autosomal dominant
inheritance with incomplete penetrance. In those cases, modifying alleles can prevent
development of the disease in individuals carrying the pathogenic variant. For example,
variants in PRPF31 can cause autosomal dominant retinitis pigmentosa through
hemizygous insufficiency30. However, a variant in CNOT3 upregulates the expression of
PRPF31, thereby increasing the expression of the wildtype allele to a level that is
sufficient to meet the needs of the cell. Family members with the
How different cell types contribute to retinal degeneration
Typically mutations that cause retinal degeneration are in genes expressed in the
photoreceptors or the retinal pigment epithelium (RPE), although not necessarily
exclusively expressed in those cell types. Photoreceptor degeneration is often the first
stage of retinal degeneration, so it follows that mutations in photoreceptor genes can
directly affect photoreceptor viability. The RPE provides structural and trophic support
to the photoreceptors, and mutations there can also have a direct impact on photoreceptor
viability. Rarely, mutations in genes in the choroid, like CA4, can also cause retinal
degeneration through a more complicated mechanism.
Photoreceptors are uniquely susceptible to degeneration due to their high metabolic load,
high protein turnover and unique structure32-34. Each photoreceptor has an outer segment
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containing stacks of membrane (called discs) and is connected to the cell body by the
connecting cilium35. Each disc contains the proteins needed for phototransduction36. All
of the proteins in the outer segment must be trafficked through the connecting cilium37.
Any deficit in cilia trafficking (such as those caused by mutations in RPGR, ALMS1 or
ARL3) can have a profound detrimental effect on the outer segments. The structure of the
outer segment ensures that almost every particle of light will hit a disc and induce the
phototransduction cascade but it also makes the cell particularly dependent on the
primary cilia. Mutations in genes responsible for cilia structure and maintenance (such as
CEP29 and, MAK) or in disc structure (like PRPH2 and ROM1) can cause retinal
degeneration by destabilizing the outer segment or prevent the outer segment from
forming properly38. Mutations in proteins involved in the phototransduction cascade
(such as RHO, SAG and PDE6B) prevent proper regulation of the ion channels involved
in phototransduction39. Excess or deficiency in ions, especially calcium, can induce
apoptosis40. Mutations in transcription factors like CRX and NR2E3 result in
photoreceptor degeneration by impairing and altering development, thereby preventing
proper photoreceptor formation41,42. Meanwhile, mutations in splicing factors (which
include PFPF3, PRPF8 and PRPF31) appear to affect photoreceptor viability more
indirectly43. It is still unknown why mutations in ubiquitously expressed splicing factors,
which are required by every cell type, can cause tissue specific deficits. One theory is
that the especially high protein turnover in the photoreceptors is responsible for their
unique susceptibility to heterozygous mutations in splicing factors44. The discs in the
outer segments have constant turn over as the older discs are phagocytized by the RPE45.
This requires a constant replenishment of phototransduction proteins and disc structural
5

proteins. If splicing is impaired, it is hypothesized that not enough of these proteins are
produced resulting in destabilized discs or dysfunctional phototransduction.
Interestingly, while mutations in proteins involved in most of these cellular functions are
either recessive or a mix of dominant and recessive, all known mutations in splicing
factors that cause retinitis pigmentosa are dominant due to haploinsufficincy46.
Genes expressed primarily or exclusively in the RPE can also cause retinal
degeneration47. The RPE provides trophic support to the photoreceptors48. Mutations in
genes involved in metabolic support to the retina will have a direct impact on
photoreceptor viability. The RPE also plays a critical role in the retinoid cycle, which is
essential in order to provide 11-cis-retinal (a necessary substrate for phototransduction) to
the photoreceptor outer segments49. During phototransduction, 11-cis-retinal is converted
to all-trans-retinal and the RPE must convert it back to 11-cis-retinal before sending it
back to the phtoreceptors49. This process can be disrupted by mutations in enzymes and
transport proteins in the RPE including RPE65, IRBP, RDH5 and LRAT50. The RPE also
plays a necessary role in disc turnover51. Preventing efficient phagocytosis of
photoreceptor outer segments (such as by mutations in MERTK) can be toxic to the
photoreceptors52.
Mutations in the choroid, the vascular layer of the eye, can also cause retinal
degeneration but are much less common than mutations in the RPE or photoreceptors.
CA4 mutations cause RP by preventing proper pH balance in the eye53. Gyrate atrophy,
which causes choroid and retinal atrophy, is caused by mutations in OAT. Ornithine
Aminotransferase (OAT) deficiency causes a buildup of ornithine which is toxic to the
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choroid and RPE54. These causes of retinal degeneration are very rare and it is unlikely
that many of the unidentified causes of retinal degeneration are from genes expressed
primarily in the choroid.
Next generation sequencing for inherited retinal degeneration
It used to be very expensive and time consuming to identify the disease causing
mutation(s) in patients with retinal degeneration. Unlike diseases like cystic fibrosis that
only have one gene to screen for mutations, over 140 genes have been identified that
cause retinal degeneration with a significant number of genes still unknown33. With the
advent of next generation sequencing (NGS), sequencing a large number of genes has
become much quicker and more affordable than it was previously55. Clinically, APEX
microarray chips are often used to identify specific mutations in specific genes that are
known to cause disease56. This can be an effective tool if the patient has one of the
mutations screened for on the chip. However, chip arrays miss new mutations in the
genes that are being screened since they look specifically for the identified pathogenic
single nucleotide polymorphisms (SNPs)57. Sequencing is a much more thorough way to
screen for mutations in the genes that have already been identified56. Furthermore, being
able to sequence the entire genome facilitates novel gene discovery and will help to fill in
the gaps of our current knowledge about the genetics of retinal degeneration.
Novel gene discovery is beneficial for both translational and basic science. It allows us
to better identify patient populations for clinical trials and to prioritize genes based in part
on the size of the potential patient population. By discovering the missense mutations
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that are tolerated or not tolerated, we can better understand which domains are important
to the function of the protein. By finding the genes in which mutations cause retinal
degeneration, we gain a better understanding of how the retina works and what function
those proteins have in the retina.
Whole genome sequencing (WGS) is the most thorough way to screen for novel
mutations58. It allows us to find deep intronic mutations, mutations in splice sites,
mutations in regulatory regions, as well as mutations in the actual genes59,60. However,
that level of genomic coverage is not always needed. The majority of disease causing
mutations are in the exome, the protein coding portion of DNA. The exome makes up
only about 2% of the human genome. Initial screening with whole exome sequencing
(WES) could eliminate the need for more extensive sequencing in most patients. WES
can detect both mutations in the exome as well as the adjacent splice sites61. Both WGS
and WES can identify SNPs and small insertions and deletions. One major caveat of next
generation sequencing is that it is not ideal for finding large insertions and deletions.
WGS is better at detecting copy number variants (CNVs) than WES, but both require a
significant depth of coverage to detect CNVs reliably.
WES analysis has two main stages. First, the reads must be mapped onto the human
genome and the variants identified and annotated. This part of the process can now be
largely automated and the output is a list of areas where the reference genome is different
from the patient’s genome, annotated with the observed frequency in that variant in
databases like ExAC and the 1000 Genomes Project as well as the expected effect on the
protein62-66. The second stage of WES analysis is currently the bottleneck in the
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process67. Sorting through the variants to identify likely pathogenic variants cannot yet
be automated and requires a lot of assumptions to create a manageable list of candidate
genes68. Some filters can be applied easily to the dataset without a high likelihood of
filtering out the pathogenic variant69. For example, filtering by frequency of the variant
is a good first step. When dealing with a rare monogenic disease, a variant with a high
frequency is unlikely to be involved69. Removing all synonymous variants, variants that
have no effect on protein sequence, is another filter that is unlikely to remove pathogenic
variants68. Filtering for genes expressed in the affected tissue can also be beneficial.
However this list is still too long to go through every variant by hand to check for likely
pathogenic variants. Developing effective filters for retinal degeneration will help to
more quickly and accurately identify the pathogenic mutations in the patients screened
with WES.
Our goal is not only to identify the cause of retinal degeneration but ultimately to treat it.
Gene therapy is a promising approach for treating hereditary retinal degeneration. If
there is a loss of function mutation, a new copy of the gene can be inserted into the cell so
that the protein is produced and degeneration is halted. The first gene therapy for retinal
degeneration recently completed phase III clinical trials70. It is for LCA patients with
mutations in RPE65, which is an ideal candidate for gene therapy. The gene has a short
coding sequence, does not require large amounts of expression to be effective, is not toxic
when overexpressed, is expressed in an easy to transduce cell type and has a relatively
wide window for treatment71-73. Additionally, treating mutations in the RPE does not
require as high a transduction efficiency as a mutation in photoreceptors. A single RPE
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cell supports multiple photoreceptors (with a 20:1 photoreceptor:RPE ratio in the fovea)
thereby saving more cells per RPE cell transduced, while correcting a defect in the
photoreceptor would mainly help the cells that are actually transduced74.
Unfortunately, not all genes are good candidates for gene augmentation therapy. Some
genes, like USH2A and ABCA4, are simply too big for most current vectors. Adenoassociated virus (AAV), the most common vector and the one used in the RPE65 trial,
can only package about 4.7 kb which includes the ITRs, promoter and cDNA sequence of
the gene75. USH2A is over 15 kb while ABCA4 is over 6 kb76,77. Even without taking
into account the space needed for a promoter it is obvious that these genes cannot be
packaged in AAV. Furthermore, some genes are toxic if overexpressed or require a high
level of expression to prevent degeneration78. Currently, we do not have the ability to
finely tune expression levels to make them match the exogenous expression levels,
although we can select weaker, cell specific promoters to limit toxicity. Unfortunately,
using a weaker promoter would risk lowering the expression level below the therapeutic
threshold. Treating a dominant gain-of-function mutation is even more complicated. It
requires specific knock down of the mutant allele, which may vary from the wildtype
allele by a single nucleotide. The clustered regularly interspaced short palindromic
repeats (CRISPR) system or RNA interference (RNAi) may be able to be used in these
cases, but depending on the mutation, it may not be possible to achieve the needed level
of specificity with current technology79,80. Finally, there are too many different genes,
some of which affect only a handful of patients, for it to be feasible to develop a specific
gene therapy for each gene.
10

Optogenetic therapy to restore vision
Optogenetic therapy is a generic treatment that has the potential to restore visual function
to the retina regardless of the genetic cause of disease81. Although it is unlikely to result
in the same level of visual restoration as gene augmentation due to the inherent
limitations in image resolution, it would be applicable for every genetic cause rather than
only one and would not be impacted by the number of patients with a particular mutation,
size of the defective gene or the narrow treatment window to preserve photoreceptors81.
Optogenetic therapy works by inserting a light sensitive ion channel into the desired cell
type so that it hyperpolarizes or depolarizes the cell directly in response to light82,83.
Essentially, the goal of optogenetic therapy is to turn other cell types in the retina into
photoreceptors after the photoreceptors have died or stopped functioning.
There are several potential targets for optogenetic therapy. The four most promising
possibilities are: remnant cone cell bodies, ON bipolar cells, AII amacrine cells and
ganglion cells81. Targeting halorhodopsin to remnant cone cell bodies induces them to
hyperpolarize in response to light, mimicking their normal light response84. Remnant
cone cell bodies are cone photoreceptors which no longer have outer segments. They
would not be as sensitive to light as normal photoreceptors or have as large of a response,
but all retinal processing would be preserved. Early studies in mice have successfully
used this approach to restore light mediated behavioral responses as well as the
electrophysiological response to light in the retina85. However, eventually the remnant
cone cell bodies would likely die, thereby limiting the long term viability of this

11

treatment option. Optogenetic therapy is designed to restore function, not to halt or even
slow cell death.
The second most attractive target is ON bipolar cells. If channelrhodopsin is expressed in
ON bipolar cells, the cells depolarize in response to light86-88. Normally the ON bipolar
cells would depolarize in response to the decrease in glutamate release from the
photoreceptors. Like all optogenetic therapy, the light sensitivity is lower than what is
seen in healthy photoreceptors, but with the advancements being made in engineering
more sensitive channelrhodopsins this will become less of a problem89,90. We can
specifically target ON bipolar cells by using the GRM6 promoter86. This helps to retain
more of the retinal processing since the OFF pathway would not be activated, which
could confuse or cancel out the signal.
Targeting the AII amacrine cells would allow activation of the ON pathway as well81.
AII amacrine cells connect the rod bipolar cells to the cone bipolar cells91. They
depolarize in response to glutamate release from the rod bipolar cells92. AII amacrine
cells are connected to ON cone bipolar cells by gap junctions, causing the ON cone
bipolar cells to depolarize as well92. In addition to the excitatory output to the ON
pathway, AII amacrine cells form inhibitory synapses with OFF bipolar cells thereby
simultaneously exciting the ON pathway and inhibiting the OFF pathway92. Targeting
AII amacrine cells may allow for more inhibition of the OFF pathway while retaining the
ON pathway stimulation.
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Ganglion cells are the final target for optogenetic therapy93,94. Ganglion cells are the
cells responsible for retinal output to the brain. Targeting ganglion cells would remove
all or most retinal processing of the visual signal. However, retinal degeneration and
retinal remodeling are less likely to affect the quality of the visual signal over time.
Currently we do not have promoters that are specific to ON vs OFF ganglion cells and
instead must target both and hope that the neuroplasticity is able to adjust to the new
input (an OFF cell becoming an ON cell).
The final strategy for optogenetic therapy is to use a ubiquitous promoter that will turn
any cell transduced into a photoreceptor cell85,95. The advantage of this strategy is the
higher expression levels achieved by ubiquitous promoters. More cells total would be
responding to light which could increase the sensitivity of the treated retina. However,
both the ON and OFF pathways would be activated simultaneously. Activating an
excitatory and inhibitory cell at the same time could cause them to cancel out or at least
diminish the signal. We do not know the limits of retinal plasticity and brain plasticity so
it is undetermined whether a completely non-targeted therapy would result in a usable
retinal signal or if the brain would interpret it as essentially gibberish.
Retinal remodeling and optogenetic therapy
One of the most important factors for successful optogenetic therapy is understanding the
effect of retinal remodeling on the therapy (and vice versa). There is a lot that we still do
not understand about retinal remodeling. It used to be assumed that the inner retina
remained largely unchanged during degeneration. This is now known to be untrue. At
13

late stages of retinal degeneration the inner retina can undergo profound changes96-101.
Studies in rd10 mice have been done which detail some of the effects of retinal
remodeling102,103. Rd10 mice have a fast rate of retinal degeneration with only a single
layer of photoreceptors remaining at P45102. The first sign of retinal remodeling is
retraction of the rod bipolar cell dendrites and mislocalization of mGluR6 from the
dendrites to the cell body and axon103. While inner retinal cell death is much slower than
photoreceptor degeneration, about a quarter of the rod bipolar cells and horizontal cells
degenerated after 9 months in the rd10 mice103. Various cell types start to migrate to
new positions, including RPE cells invading the neural retina, ganglion cells migrating
into the inner plexiform and inner nuclear layers, and bipolar cells migrating up to the top
of the inner nuclear layer98. Ectopic synapses form between all cell types and the
expression profiles of the cells change98,104. These changes have the potential to greatly
affect the long term efficacy of optogenetic therapy.
Overall, in order to better treat retinal degeneration, we need to thoroughly understand
both the genetics of retinal degeneration as well as the changes that occur to the retina
over the course of retinal degeneration. Tools like whole exome sequencing and
optogenetics are allowing us to evaluate the degenerate retina more thoroughly than was
previously possible. Here, we develop a screening process for whole exome sequencing
data to identify pathogenic mutations using genes known to be linked to retinal
degeneration and identify subjects who are good candidates for novel gene discovery.
We also evaluate the utility of the GRM6 promoter for optogenetic therapy targeting ON
bipolar cells. While a generic treatment is needed for retinal degeneration, our data
14

shows that the GRM6 promoter does not remain specific to bipolar cells in advanced
stages of retinal degeneration. The work presented here will help us to better understand
both the genetic cause and subsequent genetic regulation within the retina and hopefully
bring us closer to being able to effectively treat inherited retinal degeneration.
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Abstract:
Background: Accurate clinical diagnosis and prognosis of retinal degeneration can be
aided by the identification of the disease causing genetic variant. It can confirm the
clinical diagnosis as well as inform the clinician of the risk for potential involvement of
other organs such as kidney disease. It also aids in genetic counselling for affected
individuals who want to have a child. With the advent of next generation sequencing,
identifying pathogenic mutations is becoming easier, especially the identification of
novel pathogenic variants.
Methods: We used whole exome sequencing on a cohort of 69 patients with various
forms of retinal degeneration. All potential pathogenic variants were verified by Sanger
sequencing and, when possible, segregation analysis of immediate relatives. Potential
variants were identified by using a semi-masked approach in which rare variants in
candidate genes were identified without knowledge of the clinical diagnosis (beyond
“retinal degeneration”) or inheritance pattern. After the initial list of genes was
prioritized, genetic diagnosis and inheritance pattern were taken into account.
Results: We identified the likely pathogenic variants in 64% of the subjects. 7% had a
single heterozygous mutation identified that would cause recessive disease and 13% had
no obviously pathogenic variants and no family members available to perform
segregation analysis. Eleven subjects are good candidates for novel gene discovery.
Two de novo mutations were identified that resulted in dominant retinal degeneration.
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Conclusion: Whole exome sequencing allows for through genetic analysis of candidate
genes as well as novel gene discovery. It allows for an unbiased analysis of genetic
variants to reduce the chance that the pathogenic mutation will be missed due to
incomplete or inaccurate family history or analysis at the early stage of a syndromic form
of retinal degeneration.
Keywords: retinal degeneration, genetic diagnosis, retinitis pigmentosa, Leber congenital
amaurosis, cone-rod dystrophy, whole exome sequencing
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Introduction:
Many forms of retinal degeneration result from genetic mutations including Leber’s
congenital amaurosis (LCA), retinitis pigmentosa (RP), Stargardt’s disease and cone-rod
dystrophy. Many different genes have been discovered that, when mutated, lead to
retinal degeneration. For LCA alone, mutations in 18 different genes have been
discovered to be pathogenic, with about 30% of cases having no known genetic cause1,2.
Retinitis pigmentosa can be caused by mutations in any one of over 80 different genes
with many cases still having an unknown cause3-5. While there has been great progress in
identified disease-causing mutations for retinal degenerative diseases, this presents a
staggering problem to the clinician: what is the most efficient and cost-effective test for
identifying the genetic diagnosis?
Discovering genes that cause retinal degeneration when mutated and the specific
mutations that do or do not cause disease is important to advancing the field. If the
pathogenic mutation(s) can be identified in every patient with retinal degeneration we
will know how prevalent those mutations are, will be able to provide accurate prognoses,
and will be better able to define potential patient populations for clinical trials. With the
growing potential of novel strategies using gene editing (such as use of Clustered
Regulatory Interspaced Short Palindromic Repeats (CRISPR)) to correct specific genetic
mutations, identifying not only the gene but the specific mutations in each patient is
becoming even more important. Identifying pathogenic variants in retinal degeneration
benefits basic science as well as clinical research. By identifying the genes that result in
retinal degeneration when mutated, we gain a better understanding of how the retina
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works, which proteins are necessary for the various cellular processes that take place in
the retina, and how they interact. By defining the specific mutations that are pathogenic
(and which ones are tolerated) we better understand the function of those proteins and
domains. This information can also be used to develop gene-based treatments (i.e. gene
therapy).
The present report reviews our own experience in seeking genetic diagnoses for retinal
degeneration patients seen over a 5 year period at ophthalmology clinics at the University
of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia as well
as other patients who self-referred who agreed to participate in our molecular genetic
research study. We carried out preliminary screens of these individuals in an attempt to
identify known disease-causing variants. We followed up with whole exome sequencing
(WES). Finally, we assessed the efficiency of making the correct genetic diagnosis using
these techniques.
Methods:
Recruitment: Individuals seen in the Scheie Eye Institute and The Children’s Hospital of
Philadelphia retina clinics who were found to have a degenerative condition (and first
degree relatives) were invited to submit a blood sample for molecular genetics research
testing. Study procedures were approved by the University of Pennsylvania IRB
(#808828) and each individual provided signed informed consent.
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Whole Exome Sequencing:
Purified, target enriched genomic samples from 69 patients with various form of retinal
degeneration (including LCA, RP, Stargardt’s disease, cone rod dystrophy and
achromatopsia) to the Penn Genome Frontiers Institute (PGFI) were evaluated by whole
exome sequencing (see table 2-1). Samples had previously been screened using Asper
Ophthalmics (Tartu, Estonia) arrayed primer extension multi-gene panels for the relevant
disease and no disease-causing variants had been identified. Target enrichment was
performed with the Agilent SureSelect target enrichment system (Agilent Technologies,
Santa Clara, CA)and the sequencing was performed on Illumina HiSeq2000 (San Diego,
CA).
Mapping and variant identification:
Mapping and variant identification was performed using Galaxy6. The FASTQ files for
each patient were mapped to the reference human genome (hg18) using BurrowsWheeler Aligner for Ilumina (BWA for Ilumina). Variants were identified using
freebayes7.

Variants were annotated using Annovar8.

Identifying variants of interest:
A semi-masked analysis was used to identify potentially pathogenic mutations without
knowledge of the type of retinal degeneration. We created a curated list of genes linked
to any form of retinal degeneration and used a python script (www.python.org) to create a
customized list of potential pathogenic variants for each patient. That list consisted of
retinal degeneration genes with variants with an allele frequency of less than 0.05. Those
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mutations were then prioritized based on mutation type and known facts about the
mutations from dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/) and the Universal
Protein Resource (UniProt; http://www.uniprot.org) (known to be benign, known to be
pathogenic, novel variant, etc.). We then checked if the variants were consistent with the
clinical diagnosis and performed segregation analysis when possible.
We verified the possible pathogenic mutations in the patients and relatives via PCR using
Phusion polymerase (New England Biolabs; Ipswich, MA) and custom primers made by
Invitrogen (Carlsbad, CA) followed by Sanger sequencing by the Penn Genomics
Analysis Core. The sequences were visualized using SnapGene software (from GSL
Biotech, Chicago, IL; available at snapgene.com).
Results: We identified the pathogenic mutations in 44 of the subjects (65%). 66 different
mutations were found in 26 different genes. 18 of these mutations are completely novel
and not listed in dbSNP. 11 more are extremely rare, have no prediction on pathogenicity
and are not in any published study (See supplement for specific mutations in each form of
retinal degeneration).
De Novo Mutations:
De novo mutations pose a particular problem when trying to identify pathogenic
mutations. Dominant de novo mutations appear to be recessive when looking at the
family history. We found two de novo mutations in our patient cohort. The first was a
novel frameshift mutation in OTX2, a known mutational hotspot, in a patient with Leber’s
congenital Amaurosis (LCA; Table 2-2; JB275). OTX2 is a transcription factor that is
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essential for development of the brain and retina. All known mutations are autosomal
dominant. Knockout of OTX2 is embryonic lethal in mice due the absence of the
forebrain and midbrain9. OTX2 is essential for photoreceptor differentiation as well as
pituitary development. Knockout of OTX2 in mouse retinal cells results in a failure to
develop photoreceptors10. OTX2 mutations can result in syndromic microphthalmia,
combined pituitary hormone deficiency, and early-onset retinal dystrophy with or without
pituitary dysfunction11-13. The frameshift mutation was not present in either parent.
Another subject presented with cone dystrophy beginning at age 15. Neither parent had
any form of retinal degeneration so it was presumed that the genetic cause was recessive.
Upon analysis of the WES dataset, we found that the proband was heterozygous for a
p.Y99C mutation in GUCA1A (Table 2-2, JB185), a well characterized dominant
mutation leading to cone dystrophy14. Neither parent carried the p.Y99C mutation.
Paternity was confirmed using the whole exome sequencing results of the parents and
proband, indicating that the p.Y99C mutation was a de novo mutation.
Identification of KIF7 as a candidate gene for cone dystrophy:
A 5yo boy with cone dystrophy was found to have a compound heterozygous mutation in
KIF7 (p.H1115Q and p.Q834R)(Table 2-2; JB307). KIF7 is a cilia gene that plays an
important role in hedgehog signaling and microtubule stability16,17. KIF7 localizes to the
primary cilia, specifically the distal tip18. Mutations in KIF7 cause the cilia to become
longer than normal and disorganized18. Knockout of KIF7 in mice is neonatal lethal17.
Mutations in KIF7 have been shown to cause severe ciliopathies including Joubert
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syndrome, hydrolethalus syndrome, acrocallosal syndrome, Meckel-Gruber syndrome
and BBS19. Both variants in the patient in this study have been previously identified as
hypomorphic variants and have been seen in patients with BBS, Meckel-Gruber
syndrome and hydrolethalus syndrome20. Typically, when a missense mutation in KIF7
leads to disease, the other allele is a null allele with either a truncation or frameshift
mutation20,21. In this case, both alleles are rare hypomorphic variants (allele frequency in
1000 Genomes are 0.0010 and 0.0058 for p.Q834R and p.H1115Q respectively). In
addition to the compound heterozygous mutations, the subject was heterozygous for
mutations in several other cilia genes, including a pathogenic mutation in BBS1.
Ciliopathies have been shown to have a range of severities depending on the mutation in
the gene. For example, CEP290 mutations can result in retinal degeneration alone
(specifically LCA), syndromic ciliopathies (Joubert syndrome or Meckel syndrome) and
neonatal lethal ciliopathies. This range appears to be due the amount of functional
CEP290 that remains22. KIF7 could be similar to CEP290 in that severe mutations like
truncations and frameshifts result in more severe ciliopathies while compound
heterozygosity of hypomorphic variants may result in only retinal degeneration.
Additional mutations:
Some of the patients had potentially pathogenic mutations in additional genes linked to
retinal degeneration. Most of these additional mutations were heterozygous and therefore
unlikely to be the disease causing mutation in the patient. However, it is possible that the
heterozygous mutations, which can be tolerated in isolation, add to the mutational load
and modify the patient’s phenotype23. Five subjects had an unusually high number of
33

additional mutations (see tables 2-4 and 2-5). Some of the mutations are in genes that
interact or are in the same pathway, increasing the chances of epistatic effect.
No disease causing variants identified:
We were unable to conclusively determine the disease causing variants in 20 subjects in
the study. Five of these had a presumably recessive disease with one pathogenic or likely
pathogenic variant identified that is consistent with their disease phenotype (see table 23). These patients should be screened for copy number variants (CNVs) in the gene
identified or possibly for intronic variants. Of the remaining 20 subjects, 9 do not have
family members willing to enroll in the study. Since we did not find any obviously
pathogenic variants in the initial screening and are unable to perform segregation analysis
for the variants identified, we are unable to determine the pathogenicity of the variants
identified. One of these subjects has many known pathogenic, likely pathogenic and
novel variants but all are inconsistent with the diagnosis of adRP and we are unable to
perform segregation analysis to narrow down the disease causing variant(s) (see table 25). The remaining 10 subjects should be analyzed for novel genes that could cause retinal
degeneration (see figure 2-1).
Discussion:
Whole exome sequencing is a powerful tool to help identify new mutations in patients
who test negative for the known pathogenic mutations for retinal degeneration. However,
the majority of mutations in these patients are in genes already linked to retinal
degeneration. Forty-four of the sixty-nineprobands in our study, all whom had had
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negative screenings using gene panels for their disease, were found to harbor pathogenic
mutations in genes already linked to retinal degeneration. Thus, we found that if we
failed to find the pathogenic mutation in a patient with retinal degeneration using
standard APEX microarrays for their disease, it could be more time and cost efficient to
use targeted sequencing of all genes linked to retinal degeneration rather than whole
exome sequencing. Using a targeted sequencing approach would also allow good
coverage of the area of interest without the expense of deeper coverage of the whole
exome. When we restricted our analysis of the whole exome sequencing data to genes
linked to retinal degeneration, it allowed us to find novel mutations in those genes as well
as mutations that cause a different form of retinal degeneration.
WES is a powerful tool for identifying pathogenic mutations in genes by quickly
identifying all variants in a patient’s exome. It sequences the entire protein coding
portion of the genome, which is about 2% of the total genome. Since the non-coding
portion is not sequenced, it is cheaper than whole genome sequencing (WGS) and allows
for greater depth of coverage. The large majority of disease-‘causing variants are in the
exome, so although intronic mutations are missed, it is still usually more cost effective to
use WES and follow up with WGS or targeted sequencing if WES fails to identify the
cause of disease.
Although the size of the dataset generated by WES is smaller than WGS, sorting through
the large amount of data generated to find the relevant variants is still a challenge.
Filtering the dataset based on inheritance pattern, disease phenotype, and other
predetermined criteria can make the dataset more manageable but also risks filtering out
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pathogenic variants. De novo mutations can result in a dominant mutation in a patient
whose disease is presumed to be recessive. Dominant mutations can also be revealed by
findings of non-paternity (and concomitant incorrect family history). Diagnosis is based
on qualitative assessment and psychophysical testing and many forms of retinal
degeneration have significant phenotypic overlap with each other. A patient can be
diagnosed with a non-syndromic form of retinal degeneration when they have a
syndromic form if they have not yet developed extra-ocular symptoms. In these cases it
is easy to filter out pathogenic variants if the filters are too strict.
Limiting our initial screening to the genes that are known to cause one particular form of
retinal degeneration would have been unnecessarily restrictive. It would have placed too
much confidence in the accuracy of the clinical diagnosis when there is significant
overlap between different forms of inherited retinal degeneration. Further, at both early
and late stages of retinal degeneration, it may be difficult to distinguish one form of
disease from another. The possibility of de novo mutations and inaccurate family history
makes it impossible to determine the inheritance pattern with complete certainty even in
the best case scenario. There are also multiple genes that are linked to multiple forms of
retinal degeneration, with the mechanism by which they can differentially affect rods and
cones still not understood. It is entirely possible that a gene in which mutations are
known to cause only RP or LCA currently could in fact also have mutations that lead to
cone dystrophy. When one adds in the possibility of digenic cause and epistatic effects, it
becomes even clearer that limiting analysis by the form of retinal degeneration is overly
simplistic and can lead to missed pathogenic mutations.
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So far, most of the mutations we have found that lead to retinal degeneration follow
typical Mendelian genetics. However, many patients with retinal degeneration do not
have a known cause. It is probable that at least some of these cases will be found to be
due to the additive or epistatic effects of mutations in more than one gene. Especially in
the case of a presumed recessive inheritance pattern, the possibility that the cause is
polygenic rather than monogenic cannot be discounted. In light of that possibility,
screening all genes with mutations known to cause or contribute to retinal degeneration is
important. The fact that these genes code for proteins vital to the proper functioning of
the retina has already been established. A mutation or variant in a gene that reduces the
ability to function (but not so much that it is sufficient to cause disease in the general
population) might very well add to the mutational load that predisposes someone to
retinal degeneration.
By using a semi-masked analysis in our screening, we were able to easily identify two
patients with dominant de novo mutations as well as several with an inaccurate or
incomplete incoming diagnosis. Many of the subjects in our study self-reported the
initial diagnosis, which decreases the initial accuracy. However, there is some inherent
unreliability in the initial diagnosis for early stage retinal degeneration, particularly if this
is made by a non-specialist. Some forms of retinal degeneration, like retinitis
pigmentosa, could be a part of a syndromic form of retinal degeneration like BBS. By
not taking into account the type of retinal degeneration until after the possible mutations
have been identified, we eliminate the possibility of filtering out obviously pathogenic
variants before we even begin the analysis.
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One cautionary finding from our study is that there were several patients that had areas of
low coverage in genes of interest. One patient with Stargardt disease had a gap in
coverage in ABCA4 that masked the pathogenic mutation. Such gaps need to be filled in
with Sanger sequencing. A gap in coverage can complicate analysis if not detected as it
would essentially show no mutation in the area with no or low coverage.
We believe that all subjects should undergo appropriate psychophysical testing in order to
refine the clinical diagnosis and then undergo a panel mutation screening for that
diagnosis before being enrolled in a study for novel gene detection. This should be
followed by targeted exome sequencing of all genes linked to retinal degeneration. In our
study, 64% of the subjects were eliminated from further analysis after screening only
genes linked to retinal degeneration. Subjects with a recessive disease in which only 1
pathogenic mutation is found (7% of the patients in this study, 20% of those without a
genetic diagnosis) should be screened for CNVs and intronic variants in that gene. After
eliminating those with no relatives enrolled in the study, this would leave only 16% for a
more in depth analysis using whole exome sequencing.
The subjects with an unusually high mutational load merit further study as well. We tend
to view sporadic cases of early onset retinal degeneration as being due to an autosomal
recessive mode of inheritance, or occasionally a de novo mutation. Modifying alleles are
sometimes identified which increase the severity of the disease phenotype, like the p.
A229T variant in RPGRIP1L24. However, the consequence of multiple heterozygous
variants that can be pathogenic if there is a second mutation in the same gene has not
been studied. Screening the unaffected relatives of the three subjects with an unusually
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high mutational load could help illuminate how many mutations can be tolerated.
Studying the progression of retinal degeneration in these subjects can help show whether
the additional mutations result in a more severe phenotype or have no obvious effect.
Conclusion:
Whole exome sequencing is a very effective approach for identifying novel mutations
and narrowing down candidate genes for further analysis especially when paired with
targeted analysis based on known retinal pathways. If WES does not yield a molecular
genetic diagnosis or a likely candidate for further analysis, whole genome sequencing can
be used to identify non-coding (intronic) mutations. While analysis of the parents and
immediate family of the proband is not always required for identification of pathogenic
variants, it does increase the likelihood of identifying pathogenic variants and could be
needed if the mutations are not obviously pathogenic.
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Supplement:
Syndromic:
Three siblings in one family were diagnosed with RP. WES revealed two variants in
BBS4 in the proband (Table 2-2; JB319). The first mutation was a frameshift mutation
likely resulting in nonsense mediated decay. The second mutation was p.R295G. While
the arginine to glycine mutation is novel, an arginine to proline mutation at the same
location has been previously reported to be pathogenic, making it very likely that the
glycine substitution would be pathogenic as well25. Mutations in BBS4 have been shown
to cause Bardet-Biedl syndrome (BBS) but not non-syndromic retinitis pigmentosa.
Segregation analysis confirmed that all three siblings were compound heterozygous for
the BBS4 mutations and clinical analysis showed that their symptoms (retinitis
pigmentosa, obesity and learning difficulties) were consistent with mild BBS. Renal
dysfunction, polydactyly, and male hypogonadism are also commonly seen in BardetBiedl syndrome but were absent in this family26.
Another subject had Usher syndrome, a condition characterized by hearing loss and
retinitis pigmentosa. Clinical testing failed to reveal any known mutations leading to
Usher syndrome. WES revealed two novel frameshift mutations in GPR98 (Table 2-2;
JB324), a gene known to cause Usher syndrome when mutated27. Another subject with
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Usher syndrome was found to have two mutations in USH2A (Table 2-2, JB252) that had
been already classified as pathogenic.
Stargardt, cone dystrophy and achromatopsia:
Stargardt disease is a childhood onset macular degeneration and is most commonly
caused by mutations in ABCA4. Characteristic yellow flecks are typically seen under the
macula during a fundus exam. Five subjects presented with Stargardt disease and were
found to have mutations in ABCA4 (Table 2-2: JB260, JB333, JB358, JB16, JB320). Six
of the mutations had been previously characterized and determined to be pathogenic
while three novel frameshift mutations were found.
Autosomal dominant Stargardt disease is caused by mutations in PROM1. Interestingly,
the dominant mutations seem to cause primarily cone degeneration while the recessive
mutations can cause either rod or cone degeneration. The dominant mutations in PROM1
are typically gain of function missense mutations while the recessive mutations are loss
of function mutations including frameshift mutations, splice site mutations and
truncations. Two loss of function variants were identified in patients with either
Stargardt disease or cone dystrophy (see table 2-3; JB189, JB241). A second variant was
not identified in either case. Since a dominant inheritance pattern was not established in
these families, the pathogenicity of these variants is currently undetermined.
One subject diagnosed with Stargardt disease was found to have a heterozygous
p.V242M variant in CRX (Table 2-2; JB195). This mutation is reported to be pathogenic
and cause autosomal dominant cone rod dystrophy (CORD)28. CRX is a transcription
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factor that is required for the development and maintenance of cone photoreceptors29.
While many CRX mutations have been shown to reduce the ability of CRX to activate the
rhodopsin promoter in vitro, the p.V242M mutation did not appear to affect the ability of
CRX to activate the rhodopsin promoter, casting some doubt on the pathogenicity30. It is
possible that the p.V242M variant is pathogenic but has a different functional effect. The
variant did not segregate with disease in the family in this study. Both the mother and
half-sister are heterozygous for the variant but do not have retinal degeneration. It is
possible that the p.V242M variant contributes to mutational load or digenic cause for
disease, but based on the lack of segregation and lack of demonstrated functional effect,
the variant is probably benign.
Another subject presented with severe retinal degeneration that was classified as either
achromatopsia or LCA (Table 2-2; JB301). The proband had two novel mutations in
GNAT2, a frameshift mutation and a missense mutation. GNAT2 encodes the alpha
subunit of cone transducing which is essential for phototransduction in cones31.
Truncations are the most common pathogenic mutations in GNAT2, but pathogenic
missense mutations in GNAT2 have been seen in both patients and mice32,33.
Complicating the interpretation of the sequencing results for this subject, she had a
p.A249E heterozygous mutation in GDF6 that has been reported to be autosomal
dominant with incomplete penetrance34-36. This variant has been reported to lead to LCA,
microphthalmia and Klippel-Feil syndrome. Notably, this subject does not have any
skeletal defects that are sometimes reported to be associated with the p.A249E variant.
The mother, who does not exhibit any symptoms of retinal degeneration is positive for
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the missense variant in GDF6. Therefore, we determined that the GNAT2 mutations are
the most likely genetic cause in this subject, with the GDF6 mutation potentially acting
as a modifying allele and increasing the severity or playing no role in retinal degeneration
in this subject.
Another subject had an incoming diagnosis of LCA that was changed to cone dystrophy
upon examination. The diagnosis was further modified to achromatopsia after whole
exome sequencing revealed two heterozygous mutations in CNGB3, one of which was
novel (Table 2-2; JB426).
LCA:
LCA is a severe retinal degeneration which is symptomatic before the first year of age37.
The retinal degeneration eventually includes cone loss as well. It is one of the most
severe forms of hereditary blindness.

In this study we found mutations in five different

genes that resulted in LCA (see table 2-2). Nine of the mutations (in ABCA4, CNGB3,
KCNJ13, and PROM1) were novel.
CEP290 mutations are the most common cause of LCA. CEP290 is essential for cilia
development and maintenance38,39. Mutations in CEP290 cause many different
ciliopathies including Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome and
Senior-Loken syndrome22,39. We found a novel splice site mutation in CEP290 in one
patient with LCA (Table 2-2; JB165). The second mutation was the deep intronic splice
mutation40. This case illustrates one of the limitations of WES for finding pathogenic
mutations. Whole exome sequencing did not reveal the deep intronic mutation. Since the
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CEP290 c.2991+1655A>G mutation is the most common mutation leading to LCA, the
patient had been screened for it previously. If the mutation had not already been
identified and specifically looked for, we would not have identified the second mutation
or been able to determine if the CEP290 splice site mutation was actually disease causing
in this case or if the patient was simply a carrier for the mutation.
Mutations in PRPH2 tend to be autosomal dominant due to haploinsufficiency41.
Typically these mutations cause either retinitis pigmentosa or macular degeneration42,43.
Homozygous or compound heterozygous mutations are much rarer and cause LCA or
early onset RP when they do occur44. The parents do not always have any functional
vision loss but will usually show signs of mild retinal degeneration when examined. One
subject in this study was homozygous for a novel truncating mutation in PRPH2 (Table
2-2; JB310).
One subject was initially diagnosed with LCA. WES revealed two mutations in PDE6A
(Table 2-2; JB28) which has been shown to result in RP. Upon re-evaluation the
diagnosis was changed to early onset retinitis pigmentosa, which has a later age of onset
and typically less severe progression.
Retinitis Pigmentosa:
Retinitis pigmentosa is a progressive form of retinal degeneration that primarily affects
rod photoreceptors. It has a later onset than LCA with a typical age of diagnosis of 35
years old. There is a wide range for the age of onset with some patients diagnosed during
childhood and other being diagnosed in their 60s or even later45,46. RP can be x-linked,
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autosomal dominant or autosomal recessive. Over 80 genes have been identified that can
cause retinitis pigmentosa and the genetic cause is unknown in almost half of all patients
diagnosed47. In this study, 10 different genes were found to cause retinitis pigmentosa
with two novel mutations (see table 2-2). All of the genes have been previously shown to
cause retinitis pigmentosa.
Autosomal dominant RP (adRP) accounts for 15-40% of all cases of RP3,48. So far, more
than 20 genes have been identified that cause autosomal dominant RP3,48. These include
CA4, PRPH2 and PRPF31. Dominant mutations tend to be pathogenic either due to
heterozygous insufficiency or because they cause a toxic gain of function. Mutations in
all three of these genes seem to cause disease at least in part due to heterozygous
insufficiency as a null allele is sufficient to cause disease. The novel mutation we found
in PRPH2 is an early stop codon so we did not follow up with functional testing. The
mutations in CA4 and PRPF31 are missense mutations that are near known pathogenic
missense mutations in the genes. CA4 mutations have been shown to impair the ability
of the cells to regulate intracellular pH49. The p.Q254P mutation in CA4 (Table 2-2;
JB42) is very rare and currently classified as a variant with uncertain significance on
dbSNP (rs150432787). We were unable to perform a segregation analysis due to the lack
of DNA from family members. Interestingly, this patient was heterozygous for several
mutations that are known to cause recessive forms of retinal degeneration including
USH2A, ABCA4 and CDH23 as well as novel mutations in several other genes linked to
retinal degeneration including BBS12, ROM1 and GPR98. This is an unusually high
mutational load (see table 2-4).
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Figures:

16%

Disease causing
mutation(s) identified
Heterozygous mutation
found

13%

7%

Segregation analysis
unable to be performed

64%

No likely mutations found

Figure 2-1: Final outcome of initial screening for variants in genes associated with retinal
degeneration. Of the initial cohort of 69 subjects with retinal degeneration, the
pathogenic variants were identified in 44 subjects, heterozygous mutations consistent
with the diagnosis were identified in 5 subjects, 9 subjects had no obviously pathogenic
variants and lacked relatives willing or able to enroll in the study to perform segregation
analysis on potentially pathogenic variants. Eleven are good candidates for further
analysis to find novel genes associated with retinal degeneration.

46

Incoming Clinical Diagnosis

Number of
patients

adRP

5

Cone dystrophy

3

CORD

2

LCA

24

Macular dystrophy

1

Nanophthalmos

1

RP

15

Stargardt

11

Usher's syndrome

2

Achromatopsia

1

Vitreoschisis

1

Retinal degeneration
(unspecified)

2

Table 2-1: Breakdown of diagnoses included in this study. adRP, autosomal dominant
retinitis pigmentosa; LCA, Leber’s congenital amaurosis; CORD, cone rod dystrophy;
RP, Retinitis Pigmentosa
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Subject

Dx

gene

Nucleotide change

Protein change

dbsnp

citatio
n

JB260

Stargardt

ABCA4

c.6119G>A

p.Arg2040Gln

rs148460146

50

c.2879del

p.Ala960Aspfs*17

N/A

c.4363T>C

p.Cys1455Arg

rs758835368

c.4666del

p.Arg1556Glyfs*25

N/A

c.2588G>C

p.Gly863Ala

rs76157638

c.3984_3987del

p.His1328Glnfs*60

N/A

c.5917del

p.Val1973*

rs61751389

53

c.5917del

p.Val1973*

rs61751389

53

c.1749G>C

p.Lys583Asn

rs145265791

51

c.4594G>A

p.Asp1532Asn

rs62642574

54

c.834G>A

p.Trp278*

rs62637014

55

c.404_405insA

p.Glu135fs*23

N/A

c.513_514insA

p.Ile172Asnfs*18

rs779047261

JB333

JB358

JB16

JB320

JB249

JB319

Stargardt

Stargardt

Stargardt

Stargardt

LCA

RP (BBS)

ABCA4

ABCA4

ABCA4

ABCA4

AIPL1

BBS4
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51

52

c.883C>G

p.Arg295Gly

N/A

JB42

adRP

CA4

c.761A>C

p.Gln254Pro

rs150432787

JB165

LCA

CEP290

c.2991+1655A>G

splice mutation

rs281865192

c.3461+2TA>GT

splice mutation

N/A

c.2390del

p.Lys797Serfs*2

rs781670422

56

c.2390del

p.Lys797Serfs*2

rs781670422

56

c.597C>A

p.Tyr199*

rs267606737

57

c.597C>A

p.Tyr199*

rs267606737

57

c.883G>A

p.Glu295Lys

rs121434286

58

c.1148del

p.Thr383Ilefs*13

rs397515360

59

c.1306A>C

p.Ser436Arg

rs748354081

c.2300T>C

p.Leu767Pro

N/A

c.2300T>C

p.Leu767Pro

N/A

c.1576C>T

p.Arg526*

rs114342808

JB290

JB9

JB255

JB426

JB274

JB375

LCA

CEP290

retinal
degeneration
(Batten Disease)

CLN3

LCA (Batten
Disease)

CLN3

CORD
(Achromatopsia)

CNGB3

LCA

CRB1

RP

40

CNV suspected~

CRB1

49

60

JB402

JB38

JB301

JB324

LCA

RP

CRB1

FAM161A

LCA vs
achromatopsia

GNAT2

Usher's

GPR98

c.1429G>A

p.Gly477Arg

rs866822473

61

c.2843G>A

p.Cys948Tyr

rs62645748

62

c.3988G>T

p.Glu1330*

N/A

c.1355_1356del

p.Thr452Serfs*3

rs397704718

63

c.1355_1356del

p.Thr452Serfs

rs397704718

63

c.896C>A

p.Ala299Glu

N/A

c.720+2T>C

splice mutation

N/A

c.14767del

p.Thr4923Profs*8

rs747459491

c.17668_17669del

p.Met5890Valfs*10

rs757696771

JB185

cone dystrophy
(ad)

GUCA1A

c.296A>G

p.Tyr99Cys

rs104893967

14

JB282

LCA

GUCY2D

c.2080C>T

p.Gln694*

rs61750164

64

c.1009_1010ins

p.Asp337Alafs*61

CAGCAGCT

(p.Pro335_Ser336insSer in cis)

c.A2501A>G

p.Gln834Arg

JB307

Cone dystrophy

KIF7

50

rs138354681

20

JB32

JB181

RP

NR2E3

c.3345C>G

p.His1115Gln

rs142032413

20

c.119-2A>C

splice mutation

rs2723341

65

c.932G>A

p.Arg311Gln

rs28937873

66

c.767C>A

p.Ala256Glu

rs377257254

67

c.119-2A>C

splice mutation

rs2723341

65
68

Nanophthalmos;
maculopathy

NR2E3

JB48

RP (ad)

NR2E3

c.166G>A

p.Gly56Arg

rs121912631

JB275

LCA (ad retinal
degeneration)

OTX2

c.527del

p.Pro177*

N/A

JB28

LCA (eoRP)

PDE6A

c.1705C>A

p.Gln569Lys

rs139444207

c.1620+2T>A

splice mutation

JB33

adRP

PRPF31

c.590T>C

p.Leu197Pro

N/A

JB310

LCA

PRPH2

c.522G>A

p.Trp174*

N/A

c.522G>A

p.Trp174*

N/A

JB167

ad retinal
degeneration

PRPH2

c.136C>T

p.Arg46*

rs61755771

JB46

CORD

PRPH2

c.514C>T

p.Arg172Trp

rs61755792

51

69
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JB284

LCA

PROM1

c.2050C>T

p.R684*

rs530749007

c.2050C>T

p.R684*

rs530749007

JB44

adRP

RP1

c.2029C>T

p.Arg677*

rs104894082

70

JB372

RP

RP1L1

c.1138G>A

p.Gly380Arg

rs184332984

71

c.1138G>A

p.Gly380Arg

rs184332984

71

c.1270A>T

p.Lys424*

rs770463388

c.1270A>T

p.Lys424*

rs770463388

c.1067_1068insA

p.Asn356Lysfs*9

rs766074572

c.1067_1068insA

p.Asn356Lysfs*9

rs766074572

c.1249G>C

p.Glu417Gln

rs62636299

72

c.1102T>C

p.Tyr368His

rs62653011

73

c.767C>G

p.Ser256*

N/A

c.1084_1087del

p.Arg363Leufs*11

N/A

c.1180C>T

p.Gln394*

N/A

c.1180C>T

p.Gln394*

N/A

JB47

JB283

JB357

JB285

JB124

RP

LCA

LCA

LCA

LCA

RP1L1

RPE65

RPE65

RPGRIP1

RPGRIP1

52

JB43

JB41

JB49

JB252

RP

RP

RP

Usher's

RPGRIP1L

USH2A

USH2A

USH2A

c.171G>T

p.Leu57Phe

rs146925098

c.628A>G

p.Asn210Asp

rs146584570

c.1036A>C

p.Asn346His

rs369522997

c.13335_13337del

p.Glu4445_Asn4446delinsAsp

rs775556188

c.13297G>T

p.Val4433Leu (benign?)

rs111033381

75

c.6713A>C

p.Glu2238Ala

rs41277212

76,77

c.13207_13208del

p.Gly4403Profs*15

rs746447649

78

c.2299del

p.Glu767Serfs*21

rs80338903

74,79

74

Table 2-2: Pathogenic and probable pathogenic variants in known disease causing genes identified in subjects in this study. Only
variants that completely explain the disease phenotype were included in this table. LCA, Leber’s congenital Amaurosis; RP, retinitis
pigmentosa; BBS, Bardet Biedl Syndrome; CORD, cone-rod dystrophy; eoRP (early onset RP)
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subject

DX

gene

Nucleotide change

Protein change

dbsnp

citation

JB200

Stargardt

ABCA4

c.2828G>A

p.Arg943Gln (probable
polymorphism)

rs1801581

54

JB188

Stargardt

CNGB3

c.2139_2160del

p.Lys714_Gln720del
(p.Lys804*in cis)

(rs151039691 in cis)

59

JB23

LCA

KCNJ13 c.458C>T

p.Thr153Ile

rs863224884

JB189

Stargardt

PROM1

c.303+1G>A

splice mutation

rs777673930

JB241

cone dystrophy

PROM1

c.1623_1624del

p.Y541fs

N/A

Table 2-3: Heterozygous variants identified in subjects with recessive disease. The variant is most likely pathogenic and is consistent
with the diagnosis but we were unable to identify the second mutation. These subjects should be screened for copy number variants
and intronic variants. LCA, Leber’s congenital Amaurosis
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subject

DX

Disease
causing gene

Other genes

Nucleotide
change

Protein change

dbsnp

citation

JB333

Stargardt

ABCA4

IQCB1

c.772delA

p.Arg258Aspfs*4

N/A

JB320

Stargardt

ABCA4

RD3

c.16T>C

p.Trp6Arg

rs35649846

80

c.69G>C

p.Glu23Asp

rs34422496

80

JB9

Retinal degeneration
(Batten Disease)

CLN3

MKKS

c.1015A>G

p.Ile339Val
(hom)

rs137853909

81

JB375

RP

CRB1

AHI1

c.653A>G

p.Tyr218Cys

rs183936286

82,83

c.3257A>G

p.Glu1086Gly

rs148000791

82,84

RPGRIP1L

c.685G>A

p.Ala229Thr

rs61747071

24

JB38

RP

FAM161A

JB301

LCA vs achromatopsia GNAT2

GDF6

c.746C>A

p.Ala249Glu

rs121909352

36

JB32

RP

USH2A

c.2137G>C

p.Gly713Arg

rs696723

85

c.10246T>G

p.Cys3416Gly

rs527236140

86

NR2E3

JB181

Nanophthalmos;
maculopathy

NR2E3

ABCA4

c.2828G>A

p.Arg943Gln

rs61749446

54,87

JB184

Nanophthalmos;

NR2E3

ABCA4

c.2828G>A

p.Arg943Gln

rs61749446

54,87

55

maculopathy
JB48

RP (ad)

NR2E3

USH2A

c.10246T>G

p.Cys3416Gly

rs527236140

c.14419G>A

p.Ala4807Thr

rs534656527

86

JB275

LCA (ad retinal
degeneration)

OTX2

RP1

c.5673G>T

p.Leu1891Phe

rs139088785

JB28

LCA (eoRP)

PDE6A

IQCB1

c.962T>A

p.Val321Glu

N/A

JB284

LCA

RD3

USH2A

c.10451G>A

p.Arg3484Gln

rs771999994

76

c.13709G>A

p.Arg4570His

rs730254

76
88,89

JB41

RP

USH2A

RP2

c.844C>T

p.Arg282Trp
(hom)

rs1805147

JB49

RP

USH2A

RP1

c.4875A>G

p.Ile1625Met

rs757644601

JB195

Stargardt

unknown

CRX

c.724G>A

p.Val242Met

rs61748459

28

JB42

adRP

CA4

ABCA4

c.1140T>A

p.Asn380Lys

rs61748549

90

BBS12

c.617T>G

p.Val206Gly

N/A

CDH23

c.1096G>A

p.Ala366Thr

rs143282422

56

91

JB307

JB284

Cone dystrophy

LCA (RP)

KIF7

PROM1

GPR98

c.6017G>A

p.Gly2006Asp

rs768201036

USH2A

c.2276G>T

p.Cys759Phe

rs80338902

85

BBS1

c.1169T>G

p.Met390Arg

rs113624356

92

CEP164

c.4228C>T

p.Gln1410*

rs147398904

RPGRIP1

c.1639G>T

p.Ala547Ser

rs10151259

CLN3

c.1189G>A

p.Ala397Thr

rs754468227

RP1l1

c.6359A>G

p.Glu2120Gly

N/A

USH2A

c.13709G>A

p.Arg4570His

rs730254

76

USH2A

c.13297G>T

p.Val4433Leu

rs111033381

75

USH2A

c.10451G>A

p.Arg3484Gln

rs771999994

RP1

c.5840T>G

p.Leu1947Trp

N/A

RPGRIP1

c.3341A>G

p.Asp1114Gly

rs17103671

57

93

94

JB274

LCA

CRB1

BBS1

c.700G>A

p.Glu234Lys

rs35520756

95

ABCA4

c.3602G>T

p.Leu1201Arg

rs61750126

54

RD3

c.69G>C

p.Glu23Asp

rs34422496

80

RD3

c.16T>C

p.Trp6Arg

rs35649846

80

WFS1

c.862G>A

p.Val288Met

rs71537685

WFS1

c.1949A>G

p.Tyr650Cys

N/A

WFS1

c.2008G>A

p.Gly670Ser

N/A

KIF7

c.A2501A>G

p.Gln834Arg

rs138354681

BBS1

c.1396G>A

p.Ala466Thr

N/A

FAM161A

c.1133T>G

p.Leu378Arg

rs187695569

MAK

c.112A>C

p.Lys38Gln

N/A

RGS9

c.1351C>A

p.Gln451Lys

N/A

20

96

Table 2-4: Additional heterozygous variants of uncertain significance found in this study. These variants are unlikely to be pathogenic
in the subjects but we were unable to exclude the possibility that they act as modifying alleles. LCA, Leber’s congenital Amaurosis;
58

RP, retinitis pigmentosa; BBS, Bardet Biedl Syndrome; CORD, cone-rod dystrophy; eoRP (early onset RP). Homozygous mutations
are indicated by (hom).
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subject DX

Disease
causing gene

Other genes

Nucleotide
change

Protein change

dbsnp

Citation

JB40

unknown

RPGRIP1L

c.685G>A

p.Ala229Thr

rs61747071

24

RPGRIP1L

c.2952G>C

p.Gln984His

rs775144757

RPGRIP1L

c.196C>A

p.Gln66Lys

rs751444506

CDH23

c.1096G>A

p.Ala366Thr

rs143282422

91

CDH23

c.3293A>G

p.Asn1098Ser

rs41281310

97

FAM161A

c.977A>C

p.Lys326Thr

rs745318331

GUCY2D

c.3247C>A

p.Leu1083Met

N/A

USH2A

c.6713A>C

p.Glu2238Ala

rs41277212

77

USH2A

c.1434G>C

p.Glu478Asp

rs35730265

98

Multiplex
RP

Table 2-5: Multiple compound heterozygous mutations were identified in a subject with multiplex retinitis pigmentosa. This family
appears to have an unusually high number of recessive mutations rather than the single dominant mutation that was expected based on
the family history. We were unable to perform segregation analysis. The CDH23 mutations and RPGRIP1L mutations are the most
likely to be pathogenic.
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Abstract:
Background: Variants in PRPF31, which encodes pre-mRNA processing factor 31
homolog, are known to cause autosomal dominant retinitis pigmentosa with incomplete
penetrance. However, the majority of mutations cause null alleles, with only two proven
pathogenic missense mutations. We identified a novel missense mutation in PRPF31 in
a family with ADRP.
Methods: We performed whole exome sequencing to identify possible pathogenic
mutations in the proband of a family with ADRP. We carried out segregation analysis of
the probable mutation, PRPF13 c.590T>C. We evaluated the cellular localization of the
PRPF31 variant (p.Leu197Pro) compared to the wildtype PRPF31 protein.
Results: PRPF31 c.590T>C does segregate with disease in this family. One family
member has the mutation but is unaffected, which is consistent with previous reports the
incomplete penetrance of PRPF31 mutations. Unlike the wildtype PRPF31 protein, the
mutant PRPF31 protein (p.Leu197Pro) does not localize to the nucleus. Instead, it
localizes primarily to vesicles in the cytoplasm.
Conclusions: c.590T>C is a novel pathogenic variant in PRPF31 causing autosomal
dominant retinitis pigmentosa with incomplete penetrance likely due to protein
misfolding.
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Background:
Retinitis pigmentosa (RP) is the most common form of inherited retinal degeneration,
affecting 1 in 2500-7000 people1. Over 60 genes have been shown to cause RP2. It can
be inherited in an autosomal recessive, autosomal dominant or x-linked inheritance
pattern, with different genes associated with each inheritance pattern3. Approximately
30-40% of the cases of retinitis pigmentosa are autosomal dominant3. Dominant disease
can be due to either a toxic gain of function in which the mutation causes the protein to
have a directly toxic effect on the cell or haploinsufficiency, where half the normal
amount of protein is insufficient to fulfill the needs of the cell.
PRPF31 encodes a ubiquitously expressed splicing factor4. It links the U4/U6 complex
with U5, creating the tri-snRNP of the spliceosome5. PRPF31 mutations are known to
cause autosomal dominant RP with incomplete penetrance (RP11, OMIM 600138)4,6-11.
It is interesting that PRPF31 mutations result in a retina specific phenotype when the
splicing factor is ubiquitously expressed. A retina specific isoform has not been
identified that can explain the tissue specific susceptibility of the retina to a heterozygous
mutation in PRPF3112. The retina appears to simply have a higher dependence on this
splicing factor than other tissues. Deery et al speculated this could be due to the need to
constantly replenish disc proteins in the outer segments, resulting in a higher splicing
load than in other cell types13. It is also possible that there are splicing factors in other
cell types that can compensate for the reduced PRPF31 levels that are not expressed in
the retina.
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The incomplete penetrance seen in families with PRPF31 mutations is due to the variable
expression levels of PRPF319,10. There is a critical level of PRPF31 needed to avoid
retinal degeneration. If both alleles are wildtype, the critical level is exceeded and retinal
degeneration is avoided. However, if the expression level of one wildtype allele is high
enough, a carrier of a pathogenic allele will still reach the critical level of wildtype
protein and be asymptomatic. If the wildtype allele has an average or low level of
expression, a carrier of a pathogenic allele will develop retinal degeneration.
We identified a novel missense mutation in PRPF31. Most mutation in PRPF31 are
truncations, deletions or frameshift mutations which result in a null allele14. However,
two missense mutations have been shown to be pathogenic and are located within 20
amino acids of the novel mutation seen in the family in this study, suggesting it could be
in an important domain for protein function. We analyzed the segregation of the
mutation within the family and the impact of the mutation on localization of the protein
and concluded that it was the disease causing mutation in this family.
Methods:
Whole Exome Sequencing: Testing was carried out samples from human subjects after
obtaining written informed consent on an Institutional Review Board (IRB) approved
protocol (#808828). A sample from the proband was screened previously for mutations in
rhodopsin, peripherin/RDS and ROM1 (Carver Lab, University of Iowa, Iowa City, IA,
1995) and found to be negative. For whole exome sequencing, we performed target
enrichment using Agilent SureSelect target enrichment system and whole exome
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sequencing was performed on Illumina HiSeq2000 at the Penn Genome Frontiers
Institute (PGFI). We used Galaxy to analyze the whole exome sequencing data set15.
The FASTQ files were aligned to hg18 using BWA for Ilumina (Burrow-Wheeler
Aligner). Variants were identified with Freebayes and the variants were annotated using
Annovar16,17. We then filtered the variants to include only those in genes linked to retinal
degeneration that had an allele frequency of 0.05 or less. This yielded a short list of
genes which were prioritized based on mutation type and likelihood to cause autosomal
dominant retinitis pigmentosa. The PRPF31 variant was the strongest candidate.
Segregation Analysis: We used PCR to amplify the DNA region that included the variant
from the proband and all relatives who provided DNA using Phusion (New England
Biolabs, Ipswich, MA) and the following primers synthesized by Invitrogen (Carlsbad,
CA): GAGCCTTCCTGAGTTCCCG and GCCAAAGCCCCCATTCTAC. The PCR
product was sent for sanger sequencing at the Penn Genomics Analysis Core and
visualized using SnapGene software (from GSL Biotech (Chicago, IL); available at
snapgene.com).
Cloning: We cloned the sequences for PRPF31 from a cDNA library generated from
293T cells. We used Q5 polymerase (New England Biolabs) and custom primers
synthesized by Invitrogen. The PCR product was TOPO cloned and the sequences were
verified by Sanger sequencing at the Penn Genomics Analysis Core. The coding
sequences were cloned into an expression vector with an HA tag using In-Fusion (Takara
Bio, Mountain View, CA). The expression vector used the CMV/CBA promoter to drive
expression.
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Mutagenesis: We used site directed mutagenesis (QuikChange II Site-Directed
Mutagenesis Kit from Agilent Technologies; Santa Clara, CA) to introduce the p.L197P
variant into the cloned PRPF31 using the following primers:
GATGCGGTGCTTGGAGGCGTTCGGCTCCAGCGCCATGTCGCAG and
CTGCGACATGGCGCTGGAGCCGAACGCCTCCAAGCACCGCATC.
Transfection: ARPE19 cells were maintained in DMEM F12 media (Invitrogen)
supplemented with 10% fetal bovine serum. We plated the cells in 4 well chamber slides.
The cells were transfected using Lipofectamine LTX with plus reagent (Thermo Fisher
Scientific; Agawam, MA) and fixed 48 hours post-transfection.
Immunofluorescent staining: The ARPE19 cells were fixed for 15 minutes in 4%
paraformaldehyde. They were rinsed three times with Dulbecco’s phosphase-buffered
saline (Corning 21-030-CV). We then blocked the cells for one hour using a blocking
buffer consisting of 10% normal goat serum and 0.5% Triton X-100 in PBS. The slides
were then incubated overnight at 4 degrees with an antibody against the HA tag (Cell
Signaling Technology #3724; Danvers, MA) at a 1:800 dilution. The slides were then
incubated at room temperature for 3 hours in Alexafluor 488 Goat anti-Rabbit
(ThermoFisher Scientific A-11034). The cells were mounted using Fluoromount-G
mounting media contained 4',6-Diamidino-2-Phenylindole (DAPI). The cells were
imaged using an Olympus FV1000 confocal microscope with a 60X oil immersion
objective.
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Results:
A 37 yo woman presented with worsening vision and light sensitivity over the preceding
5 years. Previous electroretinogram (ERG) testing had shown near normal cone responses
with severe rod B wave amplitude loss. Her brother had also complained of worsening
vision. Clinical examination showed visual acuity of 20/25 in the right eye and 20/30 in
the left eye. The retinal examination showed marked vessel attenuation, waxy pallor of
the optic disc, and relatively symmetrical mid-peripheral pigment epithelial atrophy
(Figure 3-1A). There were neither bone spicules nor vitreous debris typical of retinitis
pigmentosa. Visual field testing showed an equatorial scotoma in the temporal retinas of
both eyes (Figure 3-1B). The family history was consistent with an autosomal dominant
pattern of inheritance with incomplete penetrance (see Figure 3-1C). To her memory, her
father had not received a diagnosis with any form of retinal degeneration. Two of her
brothers had been diagnosed with retinitis pigmentosa (Figure 3-1C). None of the
proband’s children (current ages 26, 30 and 32) have been diagnosed with retinal
degeneration.
Analysis of the whole exome sequencing data shows that the proband has a novel
c.590T>C (p.Leu197Pro) missense variant in PRPF31 (Figure 3-1D). This variant is not
listed in dbSNP or ExAC. Two missense mutations in PRPF31 that are known to be
pathogenic are p.Ala194Glu and p.Ala216Pro. The proximity of the new variant with
these other amino acid changes suggests that this region is an important domain for
protein function11. Since PRPF31 is a splicing factor, mislocalization from the nucleus
would essentially constitute a loss of function mutation. Both the p.Ala194Glu and
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p.Leu197Pro variants are located in the second coiled coil domain while the p.Ala216Pro
links the coiled coil to the Nop domain which is a ribonuclearprotein (RNP) recognition
motif18.
Three of the proband’s siblings (one affected, two unaffected) were tested for the
c.590T>C mutation in PRPF31 (see figure 3-1C). One affected brother was
heterozygous for the variant while two of the unaffected siblings were homozygous for
the wildtype allele. One of the unaffected siblings (sister, II-4) is a carrier for the
c.590T>C variant. In sum, the inheritance pattern is consistent with AD disease with
incomplete penetrance typically seen in PRPF31 mutations. Although the asymptomatic
carrier may continue to enjoy good vision, any children that she may have who inherit the
mutation will be at risk for retinal degeneration.
Since the previously known PRPF31 missense variant proteins mislocalize to the
cytoplasm13, we tested the cellular localization of the p.Leu197Pro variant. We cloned
the cDNA sequence for PRPF31 from 293t cells and verified that it matched the reference
sequence. We then performed site directed mutagenesis to add the c.590T>C variant.
We cloned both PRPF31WT and PRPF31L197P into expression vectors, each with driven by
a constitutive promoter (the chicken b actin promoter and cytomegalovirus enhancer
(CMV/CBA)) and the transgene was tagged with the human influenza hemagglutinin
(HA) marker. We transfected ARPE19 cells and analyzed protein localization 48 hours
post transfection with confocal microscopy. PRPF31WT localized almost exclusively to
the nucleus with a small amount of protein seen in the cytoplasm in cells with particularly
high expression (Figure 3-2). In contrast, the PRPF31L197P variant had a vesicular
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staining pattern in the cytoplasm, possibly indicating that it is being targeted for
degradation.
Discussion:
Mutations in PRPF31 are well known to cause ADRP with incomplete penetrance. Most
of these mutations are truncations, frameshifts, splicing mutations or large deletions, all
of which cause null alleles. Pathogenic missense mutations in PRPF31 are much rarer.
The universal protein resource site (uniprot.org) only lists two missense mutations
associated with RP11. The single nucleotide polymorphism database (DbSNP) only
classifies two missense variants in PRPF31 as “pathogenic”, while listing three more as
“likely pathogenic”. Given that the RP11 phenotype involves incomplete penetrance and
pathogenic missense variants are rare, functional testing is more important than usual to
establish pathogenicity. The fact that the variant PRPF31 is not localized to the nucleus
makes it impossible for PRPF31L197P to be functional as a splicing factor.
The mislocalization seen in the PRPH31 p.Leu197Pro protein variant as well as the
previously described p.Ala194Glu and p.Ala216Pro variants is interesting considering
they are unlikely to disrupt a nuclear localization signal. Ala194 and Leu197 are located
in a coiled coil domain while Ala216 is in a linker region between the coiled coil and the
NOP domain18. It seems likely that these missense mutations are destabilizing the protein
structure or disrupting protein folding and causing the protein to be targeted for
degradation. This is consistent with the staining pattern we observed for PRPF31L197P.
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Conclusions:
We conclude that the c.590T>C missense variant in PRPF31 is a pathogenic mutation
causing autosomal dominant retinitis pigmentosa with incomplete penetrance. The
phenotype is consistent with the phenotype seen from other PRPF31 mutations, the
mutation segregates with disease in the family with incomplete penetrance, and the
missense mutation causes mislocalization of the protein in vitro.
Acknowledgements: We thank the subjects for their participation in this project.
Funding: This study was funded by a Center grant from Foundation Fighting Blindness to
the CHOP-Penn Pediatric Center for Retinal Degenerations, the Brenda and Matthew
Shapiro Stewardship and the Robert and Susan Heidenberg Investigative Research Fund
for Ocular Gene Therapy, Research to Prevent Blindness, the Paul and Evanina Mackall
Foundation Trust, NIH Vision Training Grant 5T32EY007035-37, the Center for
Advanced Retinal and Ocular Therapeutics, and the F.M. Kirby Foundation.

80

Figures:

Figure 3-1: Clinical features and molecular data for PRPF31 family. A) Fundus photos
of the proband taken on her first visit (age 37). There is marked vessel attenuation, waxy
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pallor of the optic disc, and relatively symmetrical mid-peripheral pigment epithelial
atrophy. OD, right eye (ocula dextra); OS, left eye (ocula sinestra); B) Visual field testing
results of the proband. There are bilateral equatorial scotomas in the temporal retinas; C)
Pedigree for the family, which has affected members in three generations, both male and
female. The father of the proband was apparently unaffected, indicating incomplete
penetrance. DNA samples were obtained from the numbered family members. The
proband is indicated with an arrow; D) .Sanger sequencing results for the PRPF31
c.590T>C variant. The variant was confirmed in the proband (II-2) and the affected
brother (II-1). One of the unaffected sisters (II-4) is homozygous for the wildtype allele
while the second unaffected sister is a carrier for the variant (II-3).
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Figure 3-2: Localization of PRPF31WT and PRPF31L197P in ARPE19 cells as measured by
immunofluorescence for the HA tag (green). Nuclei appear blue due to staining with 4',6Diamidino-2-Phenylindole (DAPI). PRPF31L197P mislocalized to the cytoplasm while
PRPF31WT localized primarily to the nucleus. Note the vesicular staining pattern for the
PRPF31L197P construct.
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Three different missense variants in SEMA4A have been identified in retinitis
pigmentosa (RP) patients and presumed to be pathogenic: p.R354H, p.F350C and
p.R713Q1. p.R354H and p.F330C were reported to be recessive mutations while
p.R713Q was reported to be a dominant mutation. The variants were classified as
pathogenic since: 1) they segregated with the disease in the respective families, and 2)
they were not found in 100 ethnically matched normal-sighted control individuals1. Here
we review laboratory results relating to SEMA4A variants and present data that contradict
previous conclusions that particular SEMA4A variants are pathogenic.
Nogima et al created knock-in mouse lines for SemA4a missense variant2. Of the
three variants, only the p.F350C variant resulted in retinal degeneration in mice2. As the
authors mention, it is possible that the difference in SEMA4A sequence between human
and mouse can account for the differences in the effects of the variants between these two
species. However, it is also possible that the variant is not pathogenic and is merely a
benign polymorphism or a risk factor for blindness that is not sufficient to cause disease
on its own. Additional studies in the ARPE19 human retinal pigmented epithelium
(RPE) cell line demonstrated that the p.D345H and p.F350C variants do not properly
localize to the cell membrane and also cause deficits in phagocytosis or ER stress
response to oxidative stress3. Conversely, the p.R713Q variant did not affect
phagocytosis, ER stress response or protein localization3.
After obtaining consent and collecting blood samples for DNA (UPenn IRB
#808828), we analyzed whole exome sequencing data from patients with genetic forms of
retinal degeneration seen at the Scheie Eye Institute Department of Ophthalmology. We
discovered three unrelated subjects who were heterozygous or homozygous for the
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p.R713Q variant of SEMA4A. Further analyses showed that the variant did not segregate
with the disease in any of the families. The details are as follows:
Family A: This family has autosomal dominant retinal degeneration which is manifest as
retinitis pigmentosa in some individuals (II-2) and macular dystrophy in others (II-4, III1, II-1). The p.R46X mutation in PRPH2, known to be pathogenic, segregates with the
disease. The proband is a 74 year old woman with macular dystrophy (II-4, Figure 4-1A)
who has been followed for the past 39 years. While most of the relatives tested had
retinal degeneration and were heterozygous for the p.R713Q variant in SEMA4A, the
brother of the proband, II-7, was heterozygous for the SEMA4A variant (but not the
PRPH2 mutation) and had no symptoms or signs of retinal/macular degeneration.
Family B: A 43yo female (proband II-2, Figure 4-1B) presented with unilateral
pigmentary retinal degeneration. She had been symptomatic since age 19. Examination
was notable for marked asymmetry, with bone spicules and peripheral to central retinal
degeneration in the right eye only and asymmetric ERGs and visual fields. Over the next
14 years, lattice degenerative changes commenced in the left eye. Neither parent had a
history of retinal disease. The proband II-2 was diagnosed with simplex RP. Neither the
30yo son nor the 32yo daughter of the proband shows signs of retinal disease. The
proband is homozygous for the p.R713Q variant of SEMA4A. The son (III-1) and the
daughter (III-2) are heterozygous for the p.R713Q variant of SEMA4A . Based on the
pedigree of this family, it would be possible for the p.R713Q variant of SEMA4A to cause
AR disease, but it is not consistent with a dominant mutation. We were unable to
positively identify the pathogenic mutation(s) in this proband after exploring numerous
potential candidates (including common causes of AR and ADRP as well as PER3,
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HOXD1, DLEC1, ALS2CL, COL4A1, MRPS31, and STARD8). We suspect that either a
novel gene is responsible or a de novo mutation arose in the one affected retina.
Family C: An otherwise healthy 67yo male (proband II-3, Figure 4-1C) presented with
light perception only vision. An ophthalmic exam revealed widespread pigmentary
changes, retinal thinning and vessel attenuation. He had been diagnosed with simplex RP
in his 20’s. His sisters and brothers and two sons (each in their 30’s) had normal vision.
Genetic testing revealed that the proband is heterozygous for the p.R713Q variant in
SEMA4A. Three of his unaffected siblings are also heterozygous for the variant.
Additionally, his unaffected 43yo son is homozygous for the p.R713Q variant of
SEMA4A. The fact that an unaffected family member is homozygous for the mutation
indicates that this mutation is insufficient to cause disease. The pathogenic mutations in
this family is likely to be in USH2A as the proband has compound heterozygous
mutations in USH2A (p.R4192H and p.R1653*) and no other family member has
mutations in both alleles.
In summary, we describe three families with retinal degeneration and in which the
SEMA4A p.R713Q variant was observed in both affected and unaffected individuals. Our
findings are inconsistent with the dominant pattern of inheritance currently ascribed to
the SEM4A p.R713Q variant1. Not only is there a lack of segregation of the mutation with
disease, but also one of the unaffected family members in family C is homozygous for the
variant, thus eliminating the possibility that the variant leads to a recessive disease.
These results are consistent with the results from the mouse model generated by Nogima
et al that was homozygous for the p.R713Q missense Sema4a variant. This mouse did
not show any signs of retinal degeneration.2,3 It is possible that the p.R713Q missense
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Sema4a change could lead to disease when combined with a mutation in another gene,
but it is not sufficient to cause disease in isolation.
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Figures:

Figure 4-1: Family Pedigrees and clinical findings. Three families carry the p.R713Q
missense variant in SEMA4A (c.2138G>A). A) Family A has a dominant inheritance
pattern with multiple affected individuals. B) Family B has one affected member with
autosomal recessive retinitis pigmentosa. C) Family C has one affected member with
autosomal recessive retinitis pigmentosa.
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Introduction:
According to the WHO, 39 million people worldwide are totally blind
(http://www.who.int/mediacentre/factsheets/fs282/en/). For these patients, very limited or
no treatment options exist. In many cases, the underlying causes of retinal blindness are
genetic. Gene replacement and gene knockdown strategies aiming to restore vision are
being tested and move toward clinical trials for such individuals, but these therapies will
only work if the retinal neurons are still present in the patient. Additionally, it would be
prohibitively expensive to develop a gene augmentation therapy for each of the >200
different genes that contribute to blinding retinal diseases, some of which have only been
identified in a handful of patients worldwide. For many of the advanced stages of retinal
degeneration, there are no available treatments or therapies. In these patients, most of the
photoreceptor cells (rods and cones) – the light sensors of the eye, are degenerated and/or
lost.
Recently, optogenetic strategies to restore light sensitivity to the remaining cells of the
retina (photoreceptors, bipolar cells or ganglion cells) have seen considerable success in
mice1-4. Optogenetics involves the introduction of genetically encoded light sensors to
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cells to make them responsive to light. In severe retinal degeneration, targeting these light
sensors to retinal cells will create artificial photoreceptors and stimulate the remaining
retinal circuitry to function. There are a few different ways by which retinal activity can
be restored in the non-functioning retina using optogenetics, but based on what is most
well understood, three different strategies have been used in animal models5. In one
strategy, Busskamp et al. genetically targeted a light sensitive chloride channel enhanced Natronomonas pharaonis halorhodopsin (eNpHR), which hyperpolarizes in the
presence of light, to the photoreceptors present in blind mice and reported restoration of
visual responses and visually guided behavior1. In a second strategy, Lagali et al. targeted
a different light sensor that depolarizes in the presence of light – channelrhodopsin-2
(ChR2) to the ON-bipolar cells of blind mice using an ON bipolar cell (BC) specific
promoter6. These mice demonstrated an improvement in visually guided behavior and
locomotion indicating a restoration of visual function. Engineering of the ChR2 gene
gave rise to a modified version called CatCh with increased sensitivity to light and faster
channel kinetics7.. Another strategy is to target the retinal ganglion cell. Bi et al targeted
CHR2 by using a ubiquitous promoter and administering via subretinal injection. While
this strategy does result in in ganglion cell responses, it eliminates all retinal processing
and activates both ON and OFF pathways simultaneously8.
ON bipolar cells are particularly attractive targets because they would theoretically retain
the most retinal signal processing after photoreceptor cell death. In order to effectively
target the ON bipolar cells without also expressing the optogenetic protein in the OFF
bipolar cells, the murine metabotropic glutamate receptor 6 (mGRM6) promoter has been
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used as a cell specific promoter2,3. It is expressed in both the ON cone bipolar cells and
the rod bipolar cells (which are also ON bipolar cells). Since mGluR6, the protein
product of GRM6, is involved in the signal inversion necessary for the ON pathway, it is
not expressed in the OFF bipolar cells.
The 9.5 kb mGRM6 promoter was identified by Ueda et al. and used to create a
transgenic mouse line with β-galactosidase expression in the retina restricted to ON
bipolar cells9. While the expression profile was very specific, the promotor was too large
for AAV, which is currently the viral vector of choice for gene therapy targeting neural
retina. An essential 200bp enhancer sequence was identified within the full promoter that
conveys bipolar cell specific expression when paired with the ubiquitous SV40 promoter
in the wildtype mouse retina10. Adding additional copies of the enhancer increased
expression levels and specificity, with four copies achieving the optimal expression
(referred to as the 4xGRM6-SV40 promoter) 3.
Early studies have shown that 4xGRM6-SV40 promoter can be used to drive
channelrhodopsin expression in ON bipolar cells. They showed specific expression in
the ON bipolar cells of the treated wildtype (WT) mice and behavioral improvement in
rd1 mice with retinal degeneration2,3,11. However, a recent study found that bipolar cell
specific expression was not observed using the 4xGRM6-SV40 promoter in rd1 mice12.
We used the 4xGRM6-SV40 promoter and the TRPM1 promoter to drive eGFP
expression in the ON-bipolar cells of mice with retinal degeneration to test the specificity
of the promoters in the degenerate retina. The 4xGRM6-SV40 promoter drove low level
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expression in bipolar cells, ganglion and amacrine cells. Surprisingly, we occasionally
saw expression in the retinal pigmented epithelium (RPE). The TRPM1 promoter also
failed to provide ON bipolar cell specific expression in mice with retinal degeneration
whereas it drove high levels of ON bipolar expression in mice with wildtype retinas.
This dramatic change in expression profile suggests that retinal degeneration has a more
profound effect on gene expression than previously suggested and that optogenetic
therapy for late stage retinal degeneration may be better targeted to ganglion cells to
bypass all retinal processing.
Methods:
Expression constructs: The 4xGRM6-SV40-CatCh-eGFP construct was a kind gift from
Dr. Botond Roska. It was packaged it in AAV7m8 and AAV8BP2 at the Center for
Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia. For later
experiments, we removed the coding sequence for CatCh and used only 4xGRM6-SV40eGFP and that was packaged in AAV8BP2 and AAV7m8 at the CAROT Research
Vector Core. The human TRPM1 promoter was cloned from human genomic DNA by
PCR amplification (forward primer acgcgtagccactcaccagac; reverse primer
ggatccctcctgagtttgtccac) and inserted in front of the CatCh-eGFP transgene. The
TRPM1 vectors were packaged into AAV7m8 and AAV8BP2 at the Centre for advanced
retinal and ocular therapeutics (CAROT).
Animals and injections: We obtained C57Bl6/J, rd1 (C3H/HeJ), rd10 (B6.CXB1Pde6brd10/J), rd16 (BXD24/TyJ-Cep290rd16/J) and Lca5 mutant mice
97

(Lca5

Gt(AG0283)Wtsi/ Gt(AG0283)Wtsi

) from Jackson laboratory and maintained them

under a 12 hour light dark cycle (see table 5-1 for details on mouse lines). Mice were
injected with ~ 3 uL of virus either subretinally or intravitreally under isofluorane
anesthesia as previously described13. Both AAV7m9-4xGRM6-SV40-CatCh-eGFP and
AAV8BP2-4xGRM6-SV40-CatCh-eGFP were injected at a titer of 1E+13vg/ml and
AAV8b-4xGRM6-SV40-eGFP was injected at a titer of 9.48E+12vg/ml. The rd1 mice
were injected at 1 month and 8 months of age. Rd16 and rd10 mice were treated at 5
months of age at the LCA5 mice were treated at 6 months. Eyes were harvested 4-8
weeks post injection and fixed in 4% paraformaldehyde for 20 minutes. The eyes were
frozen and cryosectioned. For the TRPM1 studies, mice were injected with ~3ul
subretinally (AAV8BP2) or intravitreally (AAV7m8) – TRPM1-CatCh-eGFP at a titer of
8.19E+12vg/ml. Wildtype mice were injected at 1 month of age and eyes were harvested
one month post injection. Rd1 mice were injected at 4 weeks of age and eyes were
harvested at 4 months post injection.
Retinal explant cultures: Retinas were isolated from a 5 year old Crd1 dog with advanced
retinal degeneration post euthanasia and cultured as described previously (Cronin et al.)
for 12 days. They were then mounted on slides and imaged using the Olympus FV1000
confocal microscope with a 40X oil immersion objective.
Immunohistochemistry: The retinal sections were blocked with a blocking buffer
consisting of 10% normal goat serum and 0.5% Triton X-100 in Phosphate Buffered
Saline (PBS). We incubated the slides overnight with a rabbit anti-GFP antibody
(Thermofisher scientific #A-11122) at a 1:300 dilution. We then incubated the slides for
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three hours at room temperature with Alexafluor 488 Goat anti-Rabbit (ThermoFisher
Scientific #A-11034). We mounted the coverslips using Fluoromount-G mounting media
contained DAPI. We imaged the slides using an Olympus FV1000 confocal microscope
with a 40X and 60X oil immersion objective or with a Zeiss fluorescent microscope.
Results:
To compare transduction efficiency of the 4XGRM6-SV40 promoter in bipolar cells of
healthy and degenerating retinas, we used two different AAV serotypes- AAV7m8 and
AAV8BP2. AAV8BP2 has been shown to target the bipolar cells efficiently in wildtype
mouse retinas and to elicit ganglion cell responses in the rd1 mice (Cronin et al).
AAV7m8 can also target the bipolar cells by subretinal and intravitreal routes of injection
and has been used to target ChR2 to the ON-bipolar cells for optogenetic therapy in an
RP mouse model11. In this study, we administered AAV8BP2 or AAV7m8 containing
the 4xGRM6-SV40-CatCh-eGFP transgene cassette by subretinal injection in wildtype
(WT) and rd1 mice at P90. While CatCh-eGFP expression in the wildtype mouse retinas
was robust and restricted mostly to the ON bipolar cells, expression in the rd1 mice was
poor and not bipolar cell specific. Rather, CatCh-eGFP expression seemed to be primarily
in amacrine and ganglion cells (Figure 1). Furthermore, no improvement in visually
guided behavior (water maze) was observed compared to untreated rd1 mice (data not
shown).
We wondered whether the misexpression of 4x GRM6-SV40 promoter in the rd1 mice
was due to the degree of retinal degeneration or if the poor expression in the bipolar cells
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was due to the ectopic expression of CatCh. To eliminate these confounding factors we
performed further expression studies using the 4x GRM6-SV40 promoter driving eGFP
expression without CatCh. We injected 1 month old and 8 month old rd1 mice with
AAV8BP2- 4xGRM6-SV40-eGFP by subretinal injection and harvested the eyes 6 weeks
later. Both the young and old rd1 mice showed non-specific eGFP expression in
ganglion cells, muller glia cells and amacrine cells, but the younger mice did show a
higher level of expression in more bipolar cells than was seen in the older mice (Figure
2). Although we saw more specific eGFP expression in the younger rd1 mice, expression
in the injected region was patchy, with some areas of the retina showing exclusively
bipolar cell specific expression (Figure 3a-d), other areas having bipolar cell and nonspecific expression (Figure 3e-h and figure 3i-l), and still others showing no bipolar cell
expression at all but expression in a few amacrine or ganglion cells (Figure 3m-p).
Islands of remnant cone cell bodies seemed to be associated with areas where the
expression was exclusively in bipolar cells, suggesting that the loss of specificity is a
result of progressing degeneration. We also occasionally observed eGFP expression in
the RPE cells (data not shown).
Rd1 mice are a fast degenerating mouse model of retinitis pigmentosa where remodeling
of the inner retinal cells takes place early causing changes in the expression of
transcription factors, which could account for the loss of specific expression with the 4x
GRM6-SV40 promoter14,15. To address this concern, we tested the AAV8BP2 4xGRM6SV40-eGFP vector in different retinal degeneration mouse models (rd10, rd16 and
LCA5) having slower rates of retinal degeneration (Table 5-1). We observed poor overall
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eGFP expression (even with anti-GFP antibodies) in each of the strains of mice tested.
Islands of eGFP expression were seen in each mouse line with bipolar cell expression
observed along with expression in ganglion and amacrine cells (Figure 4). Especially
strong expression was seen in ganglion cells in the rd10 line (Figure 4e-h). Overall, we
observed a general misregulation of the 4xGRM6-SV40 promoter in four retinal
degeneration mouse models that results in non-specific expression.
It is also possible that the misregulation of gene expression is limited to the 4xGRM6SV40 promoter and to address this, we tested another bipolar cell specific promoter,
TRPM1. Interestingly, TRPM1 expression is retained in the bipolar cells even after
photoreceptor loss in the rd1 mice (Krizaj et al 2010). We cloned the human TRPM1
promoter in front of CatCh-eGFP, packaged it into AAV7m8 and AAV8P2 and injected
WT and rd1 mice between 3 and 4 weeks of age. In wildtype retinas we observed ONbipolar cell specific expression with both AAV8BP2 and AAV7m8 (Figure 5a,b). We
also observed expression in some cells of the outer nuclear layer and RPE with
AAV7m8. In rd1 mice, however, AAV8BP2 only expressed eGFP in the RPE cells
(Figure 5c), while with AAV7m8, a similar expression pattern in the inner retina as with
the 4xGRM6-SV40 promoter was seen, with eGFP expressed in amacrine and few
ganglion cells (Figure 5d). As with the 4xGRM6-SV40 promoter studies, we did not
observe improvements in navigational vision (data not shown).
To understand if these findings were species specific, we tested AAV7m8-TRPM1CatCh-eGFP in retinal explants of a Crd1 dog model of retinitis pigmentosa16. We found
a few eGFP positive cells that co-localized with the ON-bipolar cell marker GOalpha
101

(Figure 5e). We also observed eGFP positive axon terminals in the inner plexiform layer.
In previous studies we showed that the AAV8BP2-4XGRM6-SV40 promoter did drive
expression in the ON-bipolar cells of the Crd1 dog post-injection but wasn’t specific to
those cells (Ramachandran et al., 2016).
In order to determine if we could target the ON-bipolar cells with a ubiquitous promoter
more efficiently, we administered subretinal and intravitreal injections of AAV8BP2 and
AAV7m8 with a ubiquitous (CMV/CBA) promoter driving expression of eGFP in rd1
mice at six months of age. Although the transduction efficiency was lower than
previously seen in WT mice (data not shown), the viruses were still capable of
transducing bipolar cells and more efficiently with AAV8BP2 when compared to
AAV7m8 (Figure 6 a-d). These studies suggest that while we can transduce the ONbipolar cells with a ubiquitous promoter in the degenerate retina, we may not be able to
restore vision using optogenetic therapy if it requires cell specific expression.
Discussion:
Our studies show that the expression levels and expression pattern of the GRM6 and
TRPM1 promoters are significantly altered in remaining retinal cells after photoreceptors
have degenerated compared to that seen in wildtype retina. This suggests that selecting
promoters for optogenetic therapy based on expression patterns in a healthy retina is not
the best strategy. A more thorough understanding of gene expression in late stage retinal
degeneration would allow for more informed selection of cell specific promoters. The
fact that previous studies were able to restore visually guided behavior in blind mice
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using the GRM6 promoter suggests that non-specific, low level expression is sufficient
for visual function or that earlier stages of retinal degeneration retain enough GRM6
promoter activity to allow for some retention of cell specific expression. Further
exploration of cell specific promoters in a degenerate retina could result in even better
greater visual improvement after optogenetic therapy.
A simplistic assumption is that after photoreceptor degeneration, the inner retina only
experienced mild changes and remained, in essence, the same structurally and
functionally as the inner retina of a healthy retina and simply lacked signal input. This
would be ideal for optogenetic therapy. Simply add the signal at the appropriate place
and it will be treated the same as the signal in a non-degenerate retina (minus any retinal
processing that would have taken place at an earlier step). This assumption has been
disproven. The inner retina only undergoes subtle changes during the early stages of
retinal degeneration, but late stage retinal degeneration involves glial hypertrophy, cell
migration, and ectopic synapse formation17-24. These changes have the potential to
drastically affect the utility of optogenetic therapy, especially cell specific optogenetic
therapy.
Glasauer et al created a transgenic zebrafish that showed expression of a GRM6 paralog
not only in bipolar cells but also in a subset of ganglion and amacrine cells25. It is
possible that the nonspecific expression we see is due primarily to down regulation in the
bipolar cells rather than up regulation in ganglion and amacrine cells. However, the
change in the expression profile of mGluR6 in advanced retinal degeneration has been
seen in other studies12. Van Wyk et al observed nonspecific expression from the
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4xGRM6-SV40 promoter in rd1 mice, seeing even less bipolar cell expression than we
saw, likely due to the fact that they administered the virus intravitreally while we used
subretinal injections for AAV8BP212. Tehrani et al observed that mGluR6 was expressed
in a subset of ganglion cells in rats following axotomy26. It is also expressed in ganglion
cells during development26. This suggests that the retina deprived of input from the
photoreceptors, may revert to a pseudo-developmental state.
With the TRPM1 promoter, the results were surprising given the data from previous
studies that endogenous TRPM1 expression is still cell specific and expression levels
don’t change in rd1 mice27. It is possible that strain background differences or that
exogenous promoter expression is modulated in these mice in retinal degeneration.
The CMV promoter appears to be much more promising for optogenetic therapy in the
retina. Although it is non-specific, we were able to easily observe expression in the
retina while both the GRM6 and TRPM1 expression appeared to be very low and required
amplification with a GFP antibody to visualize. Intravitreal injections can be used to
largely limit the expression to ganglion cells. Further studies will have to be done to
determine whether a non-specific strategy is viable for vision restoration.
Overall, it appears that the inner retina undergoes a substantial change in expression
profiles that we do not yet understand. Some studies have been done to look at the
changes in gene expression patterns in the retina using microarrays28,29. Those studies are
a good first step towards evaluating the changes that occur in retinal remodeling, but they
do have a few major caveats. First, they use pooled cDNA from the entire retina.
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Comparing gene expression in a retina with and without photoreceptors will inherently
show up regulation of inner retina genes and down regulation of photoreceptor genes
simply because the photoreceptor population is either absent or greatly reduced. In order
to achieve a true comparison, photoreceptors would either have to be sorted out (possibly
using fluorescence-activated cell sorting) or through single cell analysis. The second
major drawback of using pooled cDNA is that it will only show changes in the average
gene expression and would not be able to determine if some cell types up regulate a gene
while other cell types down regulate the same gene. Part of what we saw was that the
4xGRM6-SV40 promoter appeared to be down regulated in the bipolar cells and up
regulated in amacrine and ganglion cells. Another study was done using in situ
hybridization in rd1 and WT mice to compare expression levels of 169 genes30. This
study provides better insight into the changes in the retina and can eliminate the
confounding factors inherent in using pooled cDNA. However, they can only evaluate
one transcript at a time and cannot conclusively identify the identity of the inner nuclear
layer cells. Considering late stage retinal degeneration involves cellular migration,
identification based on localization is especially risky. Evaluating one transcript at a time
eliminates the possibility of evaluating the concomitant up and down regulation of
multiple transcripts within the same cell.
More in depth study of the expression profiles of cells in the degenerate retina would help
us to not only target specific cell types but also to better understand the cellular responses
to photoreceptor degeneration. It is possible that the4xGRM6-SV40 promoter is being
misexpressed while the innate GRM6 promoter is less affected. Further study, including
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in situ hybridization in rd1 mice at early and late stages of retinal degeneration could
clarify whether there is up regulation of mGluR6 in other cell types. Most importantly,
selection of any cell specific promoters for use in a degenerate retina should be done in a
retinal degeneration model as opposed to WT retina.
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Table 5-1: Specific mutations and course of retinal degeneration in mouse lines used in this
study.
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Figure 5-1: Expression profile of the 4xGRM6-SV40-CaTCH-eGFP construct in WT and rd1 mice.
Note the strong and specific expression in the WT mice in contrast to the sparse amacrine cell
expression in the rd1 mice. A-C: WT mouse injected with AAV8BP2-4xGRM6-SV40-CaTCH-eGFP.
D-F: Rd1 mouse injected with AAV8BP2-4xGRM6-SV40-CaTCH-eGFP. G-I: Rd1 mouse injected
with AAV7m8-4xGRM6-SV40-CaTCH-EGFP. EGFP expression is seen in green and DAPI staining
of the nucleus is in blue. ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell
layer
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Figure 5-2: Comparison of young (injected at 1 month) and old (injected at 8 months) rd1 mice 6
weeks after injection with the 4xGRM6-SV40- EGFP in AAV8BP2. GFP fluorescence is amplified
by an anti-GFP antibody. Note the primarily bipolar cell expression in the younger mice with
more expression in the amacrine cells (white astrisks) in the older mice. A-C and D-F: 1 month
old rd1 mice injected with AAV8BP2-4xGRM6-SV40-eGFP. G-I and J-L: 8 month old rd1 mice
injected with AAV8BP2-4xGRM6-SV40-eGFP. EGFP expression is seen in green and DAPI staining
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of the nucleus is in blue. ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell
layer.

Figure 5-3: Variable expression is seen in the neural retina in different sections within the same
eye. All three sections are from a 1 month old rd1 mouse injected with 4xGRM6-SV40- EGFP in
AAV8BP2. Each row is a different section from the same eye. GFP fluorescence is amplified by
an anti-GFP antibody and choline acetyltransferase (CHAT) staining was performed to identify
ON and OFF sublamina in the inner plexiform layer. While some areas have primarily bipolar cell
expression, other areas have expression in amacrine and muller glia cells. Note the remnant
photoreceptors in the top image(D, arrow head), the transduced muller glia cell in the middle
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row (H, white arrow) and the transduced amacrine cell (L, white arrow head). EGFP expression
is seen in green, ChAT is seen in red and DAPI staining of the nucleus is in blue. ONL: outer
nuclear layer, INL: inner nuclear layer, GCL: ganglion cell layer

Figure 5-4: 4xGRM6-SV40- EGFP expression in various mouse models of retinal degeneration.
The expression construct was administered via subretinal injection packaged in AAV8BP2 . GFP
fluorescence is amplified by an anti-GFP antibody and CHAT staining was performed to identify
ON and OFF sublamina in the inner plexiform layer. The expression was not bipolar cell specific
in any of the mouse models. The white arrows (D, H, L) indicate some of the ganglion cells
expressing GFP. EGFP expression is seen in green, ChAT is seen in red and DAPI staining of the
nucleus is in blue. ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell layer
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AAV8b-TRPM1-CatCh-eGFP

AAV7m8-TRPM1-CatCh-eGFP

a

b

c

d

e

Figure 5-5: TRPM1 promoter driven expression in WT (a,b) and rd1 mice(c,d) and crd1 dog
retinal explant cultures(e). AAV7m8 or AAV8BP2. eGFP expression is seen in green, GOalpha is in
red and DAPI stains the nucleus blue.
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Figure 5-6: Comparison of tropism of different AAV capsids in rd1 mice. A-D: Retinal crosssection from adult rd1 mice injected with either AAV8BP2 (A and B) or AAV7m8 (C and D). GFP
expression was driven by the ubiquitous CMV/CBA promoter. The virus was administered
subretinally in A and C and intravitreally in B and D. ONL: outer nuclear layer, INL: inner nuclear
layer, GCL: ganglion cell layer
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Chapter 6: General Conclusions and Future Directions
Filtering Whole Exome Sequencing Results: Advantages and Disadvantages
Whole exome sequencing (WES) is a powerful tool that provides a very large data set.
Everyone has many rare variants in their exome, most of which are completely benign.
Even de novo variants are usually benign, with everyone having approximately 50 de
novo variants on average with several variants in the exome1. De novo variants are
enriched in the exome considering that it makes up only 2% of the human genome, but
even most variants in the exome are benign2. The type of mutation also serves as a poor
indicator of pathogenicity. A severe mutation like a truncation and frameshift can be
tolerated in some genes while a minor single nucleotide polymorphism (SNP) can be
pathogenic if it is in an important position in the protein3-5. Conservation of the sequence
across species can give an indication of the likelihood that a mutation at that position can
be tolerated with highly conserved areas less likely to tolerate alteration, but it is not a
guarantee that a mutation will or will not be tolerated6. Due to all this uncertainty,
variant analysis cannot be fully automated. Applying filters can make the list of potential
pathogenic variants more manageable. However, it is important to not be over-zealous in
filtering the variants. Filtering brings with it the risk of removing the pathogenic variant
before analysis even begins.
We found that screening for rare variants in a curated list of retinal genes already linked
to retinal degeneration created a manageable list of potential variants, with usually less
than 20 genes identified on each list, most of which could be eliminated quickly. We did
not filter based on whether the variants were homozygous, heterozygous or compound
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heterozygous. We found that if we took inheritance pattern into account after looking up
the rare variants instead of before, we avoided filtering out pathogenic variants.

This

allowed us to identify two subjects with de novo dominant mutations as well as one
subject diagnosed with multiplex RP who had multiple variants in several recessive
genes, suggesting that the inheritance pattern in the family may not be dominant RP but
rather a coalescence of several different forms of recessive RP. It also avoids the
differences in interpretation that can be caused by incomplete or inaccurate family history
or, in cases where one or both parents are unknown (for example, an adopted child) as
well as potential problems from a second variant that is not detected by WES such as an
intronic or a large copy number variant (CNV).
Screening first for variants in genes already linked to retinal degeneration shortens the
analysis time for subjects with easily identified mutations. Many gene variants have been
found that can cause multiple forms of retinal degeneration, depending on the exact
mutation and the presence or absence of modifying alleles. For example, PRPH2 can
cause retinitis pigmentosa or macular dystrophy7. BEST1 variants can cause vitelliform
macular dystrophy, autosomal recessive bestrophinopathy, autosomal dominant
vitreoretinochoroidopathy or retinitis pigmentosa8. Therefore, screening all genes
associated with retinal degeneration can identify novel phenotypes for mutations in genes
already known to cause retinal degeneration. Furthermore, incomplete medical or family
history, examination at an early stage of disease or examination by someone other than a
retinal degeneration specialist can lead to an incomplete or inaccurate diagnosis.
Screening all the known retinal degeneration genes eliminates the possibility of filtering
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out the pathogenic variant if the patient phenotype was mischaracterized, incomplete or
continued to develop.
Testing for Digenic Causes of Retinal Degeneration
Possibly the most interesting finding was that several of the probands had multiple
heterozygous mutations in retinal pathways. These mutations, while pathogenic or likely
pathogenic when homozygous, are generally tolerated in isolation. However, the
cumulative effect of multiple heterozygous mutations in the same pathway or protein
complex has not been extensively studied. So far, few digenic or polygenic causes of
retinal degeneration have been identified. This is in part due to the increased cost and
complexity of studying the cumulative effect of multiple mutations in the same pathway.
It is difficult to acquire enough patients with similar mutations and enough affected
family members to determine whether the mutations are likely to be pathogenic when you
are dealing with multiple genes instead of a single gene. It will be important to test the
effect of multiple mutations in the same complex. With CRISPR becoming more
widespread, we now have the tools to test the effect of heterozygous knockout in
interacting proteins in cell culture and later in animal models. One subject in our cohort
had a potential digenic cause with heterozygous mutations in BBS2 and PCM1, which are
both parts of the BBSome9. Cell models created using CRISPR and zebrafish models can
both be used to evaluate the effect of multiple heterozygous mutations in the BBSome on
cilia structure and function10-12.
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While evaluating the effect of combining specific mutations can be challenging in mice,
evaluating the effect of combined null alleles is relatively simple. There are many mouse
models of homozygous null alleles for various genes. In fact, both BBS2 and PCM1 have
mouse models with null alleles13,14. Crossing the two mouse lines will allow us to
evaluate the effect of combined heterozygous loss of function mutations in two different
genes. This is an imperfect method for evaluating the mutations since a missense
mutation could be acting as a dominant negative while a null mutation cannot. On the
other hand, if the missense mutation creates a hypomorphic allele evaluating the effect of
a null allele could actually create a more severe model and reveal an effect where the
missense mutations would not have a phenotype. It is still worthwhile to study the
combined effect of heterozygous null alleles to identify which genes will and will not
have an additive effect from heterozygous loss of function alleles.
Induced pluripotent stem cells (IPSCs) can be used to confirm a digenic cause of disease
for cilia genes like BBS2 and PCM1. The IPSCs can be differentiated to RPE or neural
progenitor cells and then the effect of gene augmentation on the cilia can be evaluated15.
If the cause truly is digenic, supplementation with either of the genes should reverse the
cilia deficits.
Of course, the effect of additional heterozygous mutations may be more subtle. Some
variants could be acting as disease modifiers, making the phenotype more or less severe
but having no effect in an unaffected individual. Modifying alleles can either affect the
mutated proteins function or trafficking or they can act by affecting the expression level
of the wildtype allele. Identifying modifying alleles and evaluating their role can be
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complicated without a large enough cohort of patients with the same mutation or a large
family with multiple affected individuals participating in the study.
Novel Gene Discovery
Trios (the parents and the proband) are needed in order to identify novel pathogenic
mutations. Without trios we cannot be sure that the mutation segregates with the disease,
which is step one in validating potential variants. It is possible to identify novel
pathogenic variants in genes already known to cause disease without parental DNA since
we already have reason to suspect that a rare variant in that gene can cause a similar
phenotype to that of the patient. It can also be possible to identify novel genes if you
have enough patients with the same diagnosis and a reason to believe that all or most
would have the same genetic cause. For example, if the disease has stereotypical
symptoms, onset and progression it is more likely to have a single genetic cause than if
the disease is highly variable in onset, progression, severity and symptoms. In our case,
we were studying a highly heterogeneous group and would not expect to see a high
number of patients with the same novel genetic cause of their disease. Without trios we
cannot reliably differentiate between a novel but benign polymorphism and a pathogenic
variant without investing significant time and resources into functional testing.
Proceeding to functional testing without segregation analysis would result in a lot of dead
ends, with most variants in novel genes likely not having a functional effect.
In this project, we identified the patients in our cohort who are the best candidates for
novel gene discovery. The next step will be to identify likely novel variants that could
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lead to retinal degeneration. One method of screening for novel genes is to filter based
on genes expressed in the retina. The retinome has been identified and can easily be used
as a filter24. However, this results in a very large list of genes, including many that are
not expressed in cell types likely to lead to the types of retinal degeneration we are
studying. For example, mutations in bipolar cells can cause congenital stationary night
blindness, but would likely not cause primary photoreceptor degeneration25. Instead of
using such a broad set of genes to filter the results, we will be using lists of genes in the
same pathway as genes that have been shown to cause retinal degeneration. Since we
maintain the lists separately, we can prioritize genes based on the specific diagnosis. If
we are unable to identify a likely pathogenic mutation from the pathway based analysis,
we can then broaden the search to include all genes known to be expressed in the RPE
and photoreceptors.
The Limits of Whole Exome Sequencing
WES has a few well known limitations. The primary drawback is that we are unable to
detect intronic variants using WES. This is usually not a problem since the majority of
pathogenic variants are located in the exome or splice sites (which are included in WES).
Some genes, like CEP290 and ABCA4 have been shown to have pathogenic mutations in
the introns16,17. Patients with LCA should always be screened for the deep intronic
variant in CEP290 before WES due to its particularly high frequency. Another type of
mutation that is missed by WES are copy number variants (CNVs). With sufficient depth
of coverage it is possible to see evidence of likely CNVs with WES but that is currently
not a reliable method of detecting CNVs18,19. Despite these drawbacks, WES is still an
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effective method of detecting pathogenic variants in most cases due to the rarity of CNVs
and intronic variants. If a pathogenic heterozygous variant is identified, the gene should
be screened for CNVs and intronic variants. If no likely pathogenic variants are
identified by WES, it then makes sense to use WGS to try to find intronic mutations and
CNVs.
Some diseases are not well suited for WES. Mutations in only three different genes have
been shown to cause Stargardt disease, with the majority of patients having mutations in
ABCA420-22. If the initial panel screening genes associated with Stargardt/macular
dystrophy comes back negative, it would be more cost and time effective to then do a
complete screening of ABCA4 for intronic variants and CNVs than to perform WES.
Only if those screens come back negative would it make sense to proceed to whole
exome sequencing. Choroideremia is only known to be caused by mutations in CHM,
many of which involve large deletions23. Evaluating choroideremia patients with WES
would provide less information at a higher cost than a thorough screening of CHM.
Characterization of Gene Expression During Retinal Degeneration: An
Interrogation using GRM6
In addition to identifying pathogenic mutations, next generation sequencing can be used
to better understand the changes that occur in the retina during retinal degeneration. As
we saw when we used the 4xGRM6-SV40 promoter, retinal cells undergo profound
structural and functional changes during degeneration. Although the inner retinal cells
remain, the expression profile is significantly changed. Single cell RNA-Seq would
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allow us to see changes in the entire transcriptome rather than evaluating gene expression
on a gene by gene basis. Evaluating the transcriptome of the retina as a whole would be
misleading due to the loss of the photoreceptors. A relative upregulation of proteins
expressed in the inner retina is to be expected since the cell population would be enriched
for those cells. Performing RNA-Seq using the entire retina would also prevent us from
being able to determine if the transcripts are being expressed in different cell types than
in the healthy retinal cells. Single cell analysis allows us to see the number and type of
cells expressing each transcript as opposed to total transcript amount.
The expression profile of the 4xGRM6-SV40 promoter appears to be similar to the
expression profile of GRM6 during development. While mGluR6, the protein encoded
for by GRM6, is restricted to ON bipolar cells in healthy adult retina, it was seen in rat
retinal ganglion cells both during retinal development and post-axotomy in WT mice26,27.
It is also upregulated in response to increased retinal pressure27. Importantly, in our gene
transfer study in the rd1 mouse, the drastic dysregulation of the promoter does not appear
to occur until there is complete loss of cone photoreceptors. In order to thoroughly
evaluate the effect of retinal degeneration on the expression profile of the GRM6-SV40
promoter, we could cross the rd1 mouse line with the transgenic mouse line expressing
GFP under the GRM6-SV40 promoter. Using a transgenic mouse line would eliminate all
confounding factors such as viral tropism, age at injection and uneven viral distribution
across the retina.
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Optimizing Optogenetic Therapy in Light of Retinal Remodeling
While retinal remodeling affects the expression profile of the cells in the retina, it is also
likely that optogenetic therapy will have an effect on retinal remodeling. The earliest
stage of retinal remodeling in rod dystrophy is for the rod bipolar cells to form synapses
on the cones28. It is possible that if we introduce channelrhodopsin in the ON bipolar
cells, it could cause ectopic synapse formation onto the ON bipolar cells, which could
cause problems with retinal processing and degrading the visual signal. The best way to
evaluate this would be to create a transgenic mouse line expressing channelrhodopsin
under the GRM6-SV40 promoter using the rd1 mouse strain29. This would allow us to
model the effect of exogenous opsin expression without including the potential variables
introduced by subretinal injection and viral transduction.
AAV8b was developed through directed evolution specifically to target bipolar cells30. If
we want to target bipolar cells in the degenerate retina, directed evolution should be done
using a degenerate retina to account for the changes in receptor expression which are
likely to affect viral tropism. Based on our results, optimizing viral tropism for the WT
retina does not appear to translate well to the degenerate retina. Using cultured human
retinal explants from donors with retinal degeneration would be the most accurate way to
predict which viral capsid will target human bipolar cells effectively. Additionally, we
should use a mouse model of retinal degeneration like the rd1 or rd10 strains since the
presence of RPE and overall ocular environment may affect viral transduction efficiency.
Ideally, the capsid selected should work well in both mice with retinal degeneration and
cultured (and eventually in vivo if warranted by safety profile) human retina. As we have
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shown here, using WT mice should be avoided as a model for optimizing optogenetic
therapy.
Assuming that promoter expression profiles will be the same in healthy and degenerate
retina has also been shown to be misleading. Instead, promoter selection and
optimization should occur in the tissue type and state that will be used. Human retinal
explants from donors with retinal degeneration could be used for initial promoter
screening. A single retina can be cultured in multiple wells, allowing for a more efficient
screen.
General Conclusion
If we want to be able to treat inherited retinal degenerations, we will need to better
understand both the genetics of the disease(s) and the changes that occur in the retina
during late stage retinal degeneration. Gene augmentation is still the best potential
treatment option for retinal degeneration, but requires the accurate identification of the
pathogenic mutations/genes. In the era of personalized medicine, we are making great
strides towards the goal of identifying the pathogenic mutation in every patient, but we
still need to optimize the genetic screening to minimize the amount of time needed to
analyze the results and to filter the variants to a manageable list. Late stage treatment
will require a thorough understanding of the retina in an advanced stage of degeneration.
Optimization of both viral serotype and promoters in degenerate retina will need to be
done for the best chance of success. The potential effect of optogenetics on retinal
remodeling remains to be determined.
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